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ABSTRACT
 The survivors of childhood cancers are often associated with adverse late effects 
including hypoplasia, fatigue, and infertility, which are characteristics of aging. However, 
the underlying mechanisms of the late effects of chemotherapy are still elusive. We have 
found that transgenic cyclooxygenase-2 (COX2) expression causes premature aging 
phenotypes. Since COX2 expression is highly induced by various chemotherapeutic 
agents, we further investigated the possible link between COX2 and the late effects of 
chemotherapy. Treatment of juvenile wild-type mice with doxorubicin (DOX), an 
anthracycline-based chemotherapeutic agent, resulted in premature aging phenotypes and 
escalated cellular senescence level in various tissues. We found that tissue expression of 
COX2 persists even 11 weeks after cessation of DOX treatment. Moreover, COX 
inhibitors successfully alleviated cellular senescence level and early aging phenotypes in 
DOX-treated mice. In addition, genetic deletion or pharmacological inhibition of COX2 
in cell lines significantly decreased DOX-induced cellular senescence. Also, treatment 
with COX inhibitors induced cell death among senescent cells, possibly through 
inhibition of p70 and Bcl signaling, consistent with our in vivo observation. Our results 
indicate that chemotherapy-induced COX2 may play an important role in the late effects 
of chemotherapy. COX inhibitors, which have been used in medical treatments for 
centuries, could serve as senolytic drugs by eliminating senescent cells to restore 
homeostasis and rescue aging phenotypes.
vi 
TABLE OF CONTENTS
DEDICATION ................................................................................................................... iii 
ACKNOWLEDGEMENTS ............................................................................................... iv 
ABSTRACT .........................................................................................................................v 
LIST OF FIGURES ........................................................................................................... ix 
LIST OF ABBREVIATIONS ........................................................................................... xii 
CHAPTER 1 INTRODUCTION .........................................................................................1 
1.1 AGING AND LATE EFFECTS OF CHILDHOOD CANCER SURVIVORS ...1 
1.2 DOXORUBICIN ..................................................................................................2 
1.3 CELLULAR SENESCENCE ...............................................................................3 
1.4 CYCLOOXYGENASE ........................................................................................5 
1.5 NONSTEROIDAL ANTI-INFLAMMATORY DRUG ......................................7 
1.6 SENOLYTIC DRUGS .........................................................................................8 
1.7 P53 ........................................................................................................................9 
CHAPTER 2 FUNCTIONAL SIGNIFICANCE OF INCREASED COX2 EXPRESSION 
DURING AGING ....................................................................................................10 
2.1 GENERATION OF INDUCIBLE COX2 TRANSGENIC MICE .....................10 
2.2 AGING PHENOTYPES IN COX2 TRANSGENIC MICE ..............................11 
2.3 INCREASED SENESCENCE IN COX2 TRANSGENIC MICE .....................13 
CHAPTER 3 DEVELOPMENT OF A MOUSE MODEL OF CHEMOTHERAPY 
-INDUCED AGING .................................................................................................29 
3.1 ANALYSIS OF AGING PHENOTYPES IN DOX-TREATED MICE ............29 
vii 
3.2 HISTOLOGICAL ANALYSIS OF TISSUE AGING .......................................30 
3.3 ANALYSIS OF CELLULAR SENESCENCE AFTER DOX TREATMENT .31 
CHAPTER 4 ROLE OF COX2 IN CHEMOTHERAPY-INDUCED CELLULAR 
SENESCENCE AND AGING .................................................................................46 
4.1 ANALYSIS OF COX2 EXPRESSION IN TISSUES OF DOX-TREATED 
MICE ..............................................................................................................46 
4.2 IN VITRO ANALYSIS OF THE EFFECT OF COX2 DELETION ON 
CHEMOTHERAPY-INDUCED SENESCENCE ..........................................46 
4.3 IN VIVO ANALYSIS OF P53 AND P21 IN DOX-TREATED MICE ............47 
4.4 THE EFFECT OF COX INHIBITOR ON AGING-PHENOTYPES IN DOX- 
TREATED MICE ...........................................................................................48 
4.5 THE EFFECT OF ASPIRIN ON DOX-INDUCED CELLULAR 
SENESCENCE IN VIVO ...............................................................................49
4.6 COX AS A TARGET TO REVERSE DOX-INDUCED AGING .....................50
4.7 COX INHIBITORS AS NEW GENERATION OF SENOLYTIC DRUGS .....52
CHAPTER 5 DISCUSSION ..............................................................................................84
CHAPTER 6 MATERIALS AND METHODS ................................................................94
6.1 GENERATION OF COX2 TRANSGENIC MICE ...........................................94
6.2 GENOTYPING AND PHARMACOLOGICAL TREATMENT OF MICE .....95
6.3 HISTOLOGY AND IMMUNOHISTOCHEMISTRY ......................................96
6.4 ISOLATION OF MOUSE LUNG FIBROBLASTS AND SA-Β-GALACTOSE 
IN VITRO STAINING ...................................................................................96
6.5 CELL CULTURE ..............................................................................................97
6.6 WESTERN BLOT ANALYSIS .........................................................................97
6.7 REAL-TIME PCR ..............................................................................................98
6.8 MTT ASSAY .....................................................................................................98
viii 
6.9 SA-B-GAL IN VIVO ASSAY ...........................................................................99
6.10 STATISTICS ....................................................................................................99
REFERENCES ................................................................................................................101
ix 
LIST OF FIGURES
Figure 2.1 Generation of COX2 transgenic mouse ............................................................16 
Figure 2.2 Expression of COX2 in various tissues of tamoxifen-inducible COX2 
transgenic mouse ......................................................................................................17 
Figure 2.3 Appearance of control and transgenic mice .....................................................18 
Figure 2.4 COX2 transgenic expression decreased subcutaneous fat ................................19 
Figure 2.5 COX2 transgenic expression slowed hair growth rate .....................................20 
Figure 2.6 COX2 transgenic expression resulted in various aging phenotypes. ...............21
Figure 2.7 Male fertility decreased after COX2 transgenic expression .............................22
Figure 2.8 Female fertility decreased after COX2 transgenic expression .........................23
Figure 2.9 H&E stained sections of pancreas from COX2 transgenic mice (TG) .............24
Figure 2.10 Immunohistochemical staining of p16 and p-H2AX......................................25
Figure 2.11 Western blot analysis of COX2, p-H2AX, and p16 .......................................26
Figure 2.12 COX2 transgenic expression increased cellular senescence level .................27
Figure 2.13 NS398 reduced percentage of senescent cells ................................................28
Figure 3.1 Mouse DOX treatment procedure ....................................................................34
Figure 3.2 DOX treatment decreased mouse body weight ................................................35
Figure 3.3 DOX treatment decreased inguinal fat weight/body weight ratio and 
epididymal fat weight/body weight ratio in mice .....................................................36
Figure 3.4 DOX treatment decreased organs weight/body weight ratio in mice ...............37
Figure 3.5 DOX treatment decreased subcutaneous fat in mice ........................................38
Figure 3.6 DOX treatment decreased muscle fiber size ....................................................39
x 
Figure 3.7 DOX treatment decreased testicle weight/body weight ratio in mice ..............40
Figure 3.8 DOX treatment decreased sperm population in mice .......................................41
Figure 3.9 DOX increases the percentage of senescent WI38 cells ..................................42
Figure 3.10 DOX induced cellular senescence in vivo ......................................................43
Figure 3.11 DOX caused cellular senescence markers, p16 and p21, in mouse tissues ....44
Figure 3.12 DOX caused cellular senescence markers, IL6, in mouse tissues ..................45
Figure 4.1 COX2 expression increased in tissues of DOX-treated mice. ..........................57
Figure 4.2 Western blot analysis for COX2 in wild-type and COX2 knockout MEFs .....58
Figure 4.3 COX2 deletion reduced DOX-induced senescence ..........................................59
Figure 4.4 Transgenic expression of COX2 increases p53 level in vivo ...........................60
Figure 4.5 p53 and p21 expression in tissues of DX-treated mice ....................................61
Figure 4.6 COX2 suppression decreased p53 level upon DOX treatment ........................62
Figure 4.7 COX2 deletion decreased p53 level upon DOX treatment ..............................63
Figure 4.8 Pharmacological treatment procedure of C57BL/6 with DOX and aspirin .....64
Figure 4.9 Aspirin partially recovered DOX-caused body weight loss and white blood 
cell (WBC) loss ........................................................................................................65
Figure 4.10 Aspirin partially recovered DOX-induced inguinal fat loss ...........................66
Figure 4.11 Aspirin partially recovered DOX-induced epididymal fat loss ......................67
Figure 4.12 Aspirin partially rescued DOX-induced sperm population decrease .............68
Figure 4.13 Aspirin partially recovered DOX-induced tissue weight loss ........................69
Figure 4.14 Aspirin partially recovered DOX-induced subcutaneous fat loss ..................70
Figure 4.15 Aspirin partially recovered DOX-induced muscle fiber size decrease ..........71
Figure 4.16 Aspirin partially recovered DOX-induced fat loss .........................................72
Figure 4.17 Aspirin partially recovered DOX-induced necrosis in mouse brain ..............73
xi 
Figure 4.18 DOX-induced cellular senescence was partially rescued by aspirin ..............74
Figure 4.19 Aspirin recovered DOX-induced the mRNA level of cellular senescence 
markers, p16 and IL6 ...............................................................................................75
Figure 4.20 Treatment schedule for COX2 knockout induction and SC-236....................76
Figure 4.21 COX2 deletion or selective pharmacological inhibition recovered DOX- 
induced body weight loss .........................................................................................77
Figure 4.22 COX2 deletion or selective pharmacological inhibition recovered monocyte 
population level under DOX treatment ....................................................................78
Figure 4.23 NSAIDs reduced viability of senescent WI38 cells .......................................79
Figure 4.24 NSAIDs decreased cellular senescence level .................................................80
Figure 4.25 NSAIDs decreased percentage of senescent cells ..........................................81
Figure 4.26 NSAIDs decreased p70, JNK, and LC3b signaling level in senescent WI38 
cells ...........................................................................................................................82
Figure 4.27 Bcl-xL signaling was decreased after treatment of COX inhibitors ...............83
xii 
LIST OF ABBREVIATIONS
CAG ......................................................... Cytomegalovirus early enhancer/chicken β-actin 
CAT............................................................................... Chloramphenicol acetyl transferase 
COX ............................................................................................................ Cyclooxygenase 
DNA .................................................................................................. Deoxyribonucleic acid 
DOX .................................................................................................................. Doxorubicin 
GPCR ........................................................................................ G protein-coupled receptors
H&E ................................................................................................. Hematoxylin and eosin
IL6 ..................................................................................................................... Interleukin-6
KO .......................................................................................................................... Knockout
mRNA ......................................................................................................... Messenger RNA
MEF ......................................................................................... Mouse embryonic fibroblast
NSAID ...................................................................... Non-steroidal anti-inflammatory drug
O.C.T...................................................................................... Optimal Cutting Temperature
PGH2.......................................................................................................... Prostaglandin H2
PLA2 .........................................................................................................Phospholipase A2
RNA ............................................................................................................Ribonucleic acid 
ROS ................................................................................................ Reactive oxygen species 
SASP ................................................................ Senescence-associated secretory phenotype
SA-β-gal ................................................................... Senescence-associated β-galactosidase
TG ........................................................................................................................ Transgenic 
WT ......................................................................................................................... Wild type 
1 
CHAPTER 1 
INTRODUCTION
1.1 AGING AND LATE EFFECTS OF CHILDHOOD CANCER SURVIVORS 
Aging is characterized by a steady decline in organ function, leading to the loss of 
physiologic reserve and frailty (Sanoff, Deal et al. 2014). Healthy aging is a process of 
adaptation to the changes of life, which allows elderly individuals to maintain their 
physical, mental, and social wellbeing (Lipshultz, Lipsitz et al. 2002). Growing evidence 
suggests that environmental factors play an important role in aging. A large number of 
mouse models to study mechanisms of aging have been developed, including models 
with mutation in genes responsible for reactive oxygen species (ROS) scavenging (Sod2), 
cell cycle check point components (AIMP3, Atm, Bub/b, p16, Trp53), DNA repair and 
maintenance (Ercc, Polg, Prkdc, Terc, Wrm, Xrcc5, Rag1), nuclear mechanical properties 
(Luna, Zmpste 24), and components in signaling pathways of Wnt or calcium-phosphate 
metabolism (Gsk3a, Kl, and Fgf23) (Harkema, Youssef et al. 2016). Although these 
models are valuable to study the effect of genetic mutation on aging, they are not 
applicable for analysis of environmental effects on aging. 
Cancer is the second commonest cause of death in children in developed 
countries, and childhood cancer and its treatment have remained a challenge for patients, 
their families, and oncologists (Kaatsch 2010). Survivors of childhood cancer are 
expected to live decades of post-cancer life. However, adult survivors of childhood 
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cancers are known to be at risk for chemotherapy-related adverse health outcomes 
(Hudson, Ness et al. 2013), resembling aging phenotypes. They should receive optimum 
care to reduce the consequences of late effects, including second malignancies, organ 
dysfunction, premature skin and ocular changes, early onset of frailty, endocrine and 
metabolic disorders, and cognitive and psychosocial problems, which may emerge many 
years, even decades, after completion of treatment (Maccormick 2006, Kremer, Mulder et 
al. 2013). While an accumulating body of evidence supports the hypothesis that cancer 
treatment is associated with accelerated aging, the mechanisms that lead to a functional 
decline or frailty remain elusive.  Additionally, while the mouse models of cancer include 
both genetic and chemically-induced models, there are no chemically-induced mouse 
models of aging. There is also the lack of a mouse model that can be used to study the 
late effects of chemotherapy. 
1.2 DOXORUBICIN 
The anthracyclines, including doxorubicin (DOX), are among the most widely 
used and successful chemotherapeutics for childhood cancers. DOX has been used in 
oncologic treatment since the 1960s. It exerts its effect by intercalating DNA to inhibit 
the progression of topoisomerase II, an enzyme which relaxes supercoils in DNA, and by 
generating ROS, which can cause oxidative stress and result in significant damage to cell 
structures (Bartlett, Trivedi et al. 2017). When it is given as single agent or in 
combination with other antitumor agents, the tumors most commonly responding to DOX 
include breast and esophageal carcinomas, osteosarcoma, Kaposi’s sarcoma, soft-tissue 
sarcomas, and Hodgkin’s and non-Hodgkin’s lymphomas (Singal and Iliskovic 1998). 
Sarcomas and lymphoblastic leukemia, common cancers in children, have been treated 
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with DOX for many years (Lipshultz, Colan et al. 1991, Lipshultz, Lipsitz et al. 1995). 
Also, between 1972 and 1987, children with acute lymphoblastic leukemia were treated 
with different doses of DOX protocols (Lipshultz, Lipsitz et al. 1995). In addition, it is 
reported that children treated with anthracyclines are at increased risk for various 
complications (Hudson, Mertens et al. 2003, Alvarez, Scully et al. 2007, Mody, Li et al. 
2008, Miller, Lipsitz et al. 2010, Harake, Franco et al. 2012). DOX is frequently 
associated with late effects including cachexia and cardiomyopathy (Bartlett, Trivedi et 
al. 2017), and DOX has been shown to induce senescence in both humans and mice 
(Sanoff, Deal et al. 2014, Demaria, O'Leary et al. 2016, Baar, Brandt et al. 2017). 
However, the mechanism behind senescence and late effects of DOX is still largely 
unknown. 
1.3 CELLULAR SENESCENCE 
Cellular senescence is a state of irreversible growth arrest, and can be triggered by 
multiple mechanisms including telomere shortening, the DNA damage, and the 
epigenetic derepression of the INK4a/ARF locus (Collado, Blasco et al. 2007). These 
mechanisms limit excessive or aberrant cellular proliferation and thus, are thought to 
protect cells against the development of cancer. Cellular senescence also has beneficial 
effects in embryonic development and wound healing, but the persistence and 
accumulation of senescent cells, usually with age, in various tissues can also impair 
function and contribute to both aging and pathogenesis of many age-related diseases 
(McCulloch, Litherland et al. 2017), like glaucoma, cataracts, the diabetes and 
osteoarthritis (Childs, Durik et al. 2015). Furthermore, senescent cells produce 
proinflammatory and matrix-degrading molecules in what is known as the senescence-
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associated secretory phenotype (SASP), which may play a causal role in diseases like 
atherosclerosis, diabetic fat, cancer, and pulmonary fibrosis (Childs, Durik et al. 2015). 
Markers of senescent cells include high expression of cell cycle regulators (p16 and p21), 
SASP factors like interleukin-6 (IL6), and an increase in senescence-associated β-
galactosidase (SA-β-gal) activity, among others (Kirkland, Tchkonia et al. 2017). Recent 
evidence also suggests that accumulation of senescent cells can disrupt normal tissue 
functioning. Through SASP, senescent cells could release a large number of pro-
inflammatory cytokines, chemokines, growth factors, and proteases. Through these 
components, senescent cells establish a secretory phenotype that could give rise to a 
systemic inflammatory situation, and is related to aging (Osorio, Barcena et al. 2012). 
Many chemotherapeutic drugs change cellular states, including the induction of 
senescence, in cancer cells and tumor microenvironment (Demaria, O'Leary et al. 2017). 
For example, DOX induces cellular senescence in human ovarian cells both in vivo and 
in vitro (Soleimani, Heytens et al. 2011), and cytotoxic chemotherapy potently induces 
the expression of cellular senescence markers, like p16INK4a(p16) in peripheral blood T 
cells (Sanoff, Deal et al. 2014). However, how chemotherapy influences cellular 
senescence and whether chemotherapy-induced cellular senescence is related to the late 
effects of chemotherapy remain to be determined. This knowledge gap is significant 
enough to hamper the progress in both basic science and translational medicine 
development. 
Thus far, researchers have been using cell lines (Soleimani, Heytens et al. 2011) 
and human tissue samples (Sanoff, Deal et al. 2014) to investigate the relationship 
between chemotherapy and senescence/aging. However, aging is a systemic process, 
5 
involving almost all the cells, tissues, and organs across the body. Researches with 
human tissue samples (Sanoff, Deal et al. 2014) is restricted since we can only check the 
senescence markers in human tissue samples and cannot manipulate them to investigate 
the senescence mechanism. At the same time, researches with cell lines (Soleimani, 
Heytens et al. 2011) are unable to examine the systemic, whole-body response to 
chemotherapy. 
1.4 CYCLOOXYGENASE 
Cyclooxygenase (COX) is a rate-limiting enzyme for the conversion of 
arachidonic acid to prostanoids, which exert their effects by activating rhodopsin-like 
seven transmembrane spanning G protein-coupled receptors (GPCRs), which, upon 
binding with prostanoids, activate the intracellular signaling (Ricciotti and FitzGerald 
2011). In the COX signaling cascade, when stimuli appear, the 20-carbon fatty acid 
arachidonic acid is freed from membrane phospholipids by phospholipase A2 (PLA2) 
and then converted to an unstable intermediate prostaglandin H2 (PGH2) by COX.  
Unstable PGH2 is quickly converted to one of five prostanoids (PGD2, PGE2, PGF2α, 
PGI2 and TXA2) by tissue-specific prostanoid synthases. Prostanoids exert their effect by 
activating a group of GPCRs. Two GPCRs, DP1 and DP2, are activated by PGD2, four 
GPCRs by PGE2 (EP1, EP2, EP3, EP4), while IP, FP and TP are activated by PGI2, 
PGF2α, and TXA2, respectively (Jiang and Dingledine 2013). 
COX exists as two related but unique isoforms: COX1 and COX2. While 
constitutive expression of COX1 is believed to play a role in tissue homeostasis, COX2 
expression is highly induced by various environmental stresses such as drugs, UV, 
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cigarette smoke, diet, and infection (Shim, Foley et al. 2010). Therefore, increased 
expression of COX2 is an indicator of both cellular and environmental stresses. 
Studies have implicated that COX2 is involved in the development and/or 
progression of age-related diseases including atherosclerosis (Cipollone 2005), arthritis 
(Woods, Mogollon et al. 2003), cancer (Sobolewski, Cerella et al. 2010), osteoporosis 
(Raisz 2005), and Alzheimer's disease (O'Banion 1999). In addition, COX2 expression is 
increased in tissues of aged humans and mice. In aged rodents, increased COX2 
expression has been reported in the heart, prostate, liver, kidney, and macrophages 
(Hayek, Mura et al. 1997, Kim, Baek et al. 2001, Badawi, Liu et al. 2004, Choi, Kim et 
al. 2014, Tung, Rodriguez-Bies et al. 2015). The increased COX2 expression has also 
been reported in the senescent tissues of aged humans, including skin, mononuclear cells, 
and kidney (Melk, Schmidt et al. 2004, Kang, Van Der Zypp et al. 2006, Habib, Salem et 
al. 2014, Surowiak, Gansukh et al. 2014). The National Institute of Aging (NIA) 
Interventions Testing Program has tested agents to evaluate their effect on the lifespan of 
genetically heterogeneous mice. Such efforts have identified that aspirin, a classical non-
steroidal anti-inflammatory drug (NSAID), which is a COX inhibitor, increases lifespan 
(Phillips and Leeuwenburgh 2004). Recent studies also reported the pro-longevity effect 
of ibuprofen (He, Tsuchiyama et al. 2014) and celecoxib (Ching, Chiang et al. 2011), 
both of which are also COX inhibitors. Caloric restriction, which is the only method 
known so far to suppress aging, decreases COX2 expression and activity (Jung, Lee et al. 
2009). COX2 is also well known for its role in inflammation, but recent studies have 
shown that this enzyme also has anti-inflammatory activity (Luo, Urgard et al. 2011), and 
COX2 can also be induced by chemotherapy treatment (Altorki, Port et al. 2005). 
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Although many studies focused on the role of chemotherapy-induced COX2 in cancer 
cells, the role of chemotherapy-induced COX2 in normal cells remains to be determined. 
1.5 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 
As the most frequently consumed drugs worldwide (Frolich 1997), NSAIDs are a 
chemically heterogenous group of agents that are widely used for their anti-inflammatory, 
antipyretic, and analgesic properties (Pirlamarla and Bond 2016). There are important 
differences amongst the various NSAIDs, which are not explained by differences in 
pharmacokinetics and are often of therapeutic relevance. The discovery of two different 
COXs, now known as COX1 and COX2, provides an explanation for these and other 
differences (Frolich 1997). NSAIDs act by inhibiting COX1 and/or COX2 (Day and 
Graham 2013), and NSAIDs are classified depending on which COX isoenzyme they 
preferentially block. Traditionally, the selective COX2 inhibitors include SC-236 
(Masferrer, Koki et al. 1999), celecoxib (Goldstein, Silverstein et al. 2000), rofecoxib, 
valdecoxib, parecoxib, etorioxib, and lumaricoxib (Pirlamarla and Bond 2016). Few sole 
COX1 inhibitors have also been identified, like resveratrol (Brzozowski, Konturek et al. 
2001). NSAIDs that inhibit both COX1 and COX2 are known as the nonselective 
NSAIDs, and include aspirin (Brzozowski, Konturek et al. 2001), sulindac (Oshima, 
Dinchuk et al. 1996), diclofenac, naproxen, ibuprofen, indomethacin, and piroxicam 
(Pirlamarla and Bond 2016). 
Aspirin is one of the oldest and most widely used NSAIDs, exerting its function 
through inhibiting both COX1 and COX2 (Brzozowski, Konturek et al. 2001, Vane and 
Botting 2003). Its related usage has been documented from 2400 years ago by 
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Hippocrates (Grammaticos and Diamantis 2008). Already approved by FDA, aspirin has 
widely used in numerous conditions like cardiovascular disease, pain, and inflammation 
(Fuster and Sweeny 2011). Studies have even shown that a regular dose of aspirin can 
prolong life since aspirin reduces the risk of many diseases associated with aging (Vane 
and Botting 2003). However, the mechanism of aspirin in preventing aging is still not 
known yet. 
1.6 SENOLYTIC DRUGS 
The numbers of senescent cells increase with aging in mice, monkeys, and 
humans, and intervention that increase lifespan, like caloric restriction is associated with 
decreased senescent cell abundance (Kirkland, Tchkonia et al. 2017). Drug AP20187 
does not affect wild-type mice, but it activates a suicide protein encoded by a transgene, 
which is present in only p16-expressing cells in INK-ATTAC transgenic mice. Using this 
INK-ATTAC mice line, from which senescent cells can be eliminated using drug 
AP20187, special removal of p16-positive senescent cells can prevent or delay tissue 
dysfunction and extend healthspan (Baker, Wijshake et al. 2011). 
To remove senescent cells pharmacologically from non-genetically modified 
mice, senolytic drugs, are being developed. Two recent studies (Demaria, O'Leary et al. 
2016, Baar, Brandt et al. 2017) have shown that selective removal of chemotherapy-
induced senescent cells ameliorates adverse effects of chemotherapy and improves tissue 
homeostasis. Recently, several senolytic drugs have been reported with the ability of 
eliminating senescent cells, including quercetin, dasatinib (Zhu, Tchkonia et al. 2016), 
ABT263 (Chang, Wang et al. 2016), ABT737 (Yosef, Pilpel et al. 2016), FOXO4-DRI 
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(Baar, Brandt et al. 2017). However, each has critical disadvantage: Quercetin, 
ABT263/737 and FOXO4-DRI are not FDA-approved, and while quercetin, dasatinib, 
ABT263/737 are non-specific (Zhu, Tchkonia et al. 2016, Baar, Brandt et al. 2017). 
Therefore, we need a drug which specifically targets senescent cells and FDA-approved, 
to quickly facilitate its therapeutic use. 
1.7 P53 
p53 is a tetrameric transcription factor and is a well-known tumor suppressor. It 
induces growth arrest or apoptosis program in response to a plethora of different cellular 
stresses (Brady and Attardi 2010). In normal cells, p53 is a short-lived protein which is 
continuously undergoing ubiquitination and subject to proteasomal degradation. MDM2, 
one of the first characterized p53 targets, serves as a major E3 ubiquitin ligase for p53 
degradation and thus forms a negative autoregulatory loop to maintain the low level of 
p53 expression in unstressed conditions (Qian and Chen 2013). Upon genotoxic stresses, 
rapid phosphorylation of p53 at Ser15 by Ataxia telangiectasia mutated (ATM), a 
serine/threonine protein kinase, and at Ser20 by checkpoint kinase 2 (Chk2) causes 
dissociation of p53 from MDM2, resulting in p53 stabilization and activation of its 
downstream processes (Qian and Chen 2013). Many DNA damage-inducing drugs target 
tumors through p53-mediated apoptosis (Rufini, Tucci et al. 2013), and in addition, they 
also induce cellular senescence (Qian and Chen 2013). The main role of p53 is to 
eliminate damaged cells, either by triggering apoptosis or senescence. However, 
uncontrolled activity of p53 results in the excessive elimination of cells that exhausts the 
capacity of tissue regeneration, leading to premature aging (Collado, Blasco et al. 2007). 
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CHAPTER 2 
FUNCTIONAL SIGNIFICANCE OF INCREASED COX2 EXPRESSION 
DURING AGING 
2.1 GENERATION OF INDUCIBLE COX2 TRANSGENIC MICE 
To investigate the role of COX2 in cellular senescence and aging, we have 
generated the COX2 transgenic mouse model using Cre-loxP system. A diagram of the 
COX2 transgene is shown in Figure 2.1. In this construct, the cytomegalovirus early 
enhancer/chicken β-actin (CAG) promoter directs the expression of the human COX2 
gene. COX2 expression is blocked by a chloramphenicol acetyl transferase (CAT) 
reporter gene flanked by two loxP sites. Two independent lines of floxed CAT/COX2 
mouse (CATflCOX2) were produced. Since embryonic expression of COX2 causes 
various malformations and postnatal lethality (Shim, Foley et al. 2010), an inducible 
COX2 transgenic mouse model was generated. CATflCOX2 mice were crossed with 
ROSA-Cre ERT2 mice carrying a Cre recombinase-estrogen receptor-T2 allele targeted 
to the ubiquitously expressed ROSA26 locus (Ventura, Kirsch et al. 2007). Tamoxifen-
inducible, Cre-mediated recombination at loxP sites results in deletion of the interfering 
CAT gene. In this way, human COX2 could be expressed under the control of the CAG 
promoter in the COX2 transgenic mouse, which has both floxed COX2 and Cre-ERT2 
alleles. COX2 transgenic mice without tamoxifen treatment appeared to be normal. To 
study the effect of COX2 in mouse, 5~6-week-old COX2 transgenic and control 
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littermates were intraperitoneally injected with tamoxifen, and mosaic expression of 
COX2 was observed in the tissues of 20-week-old COX2 transgenic mice, including the 
heart, skin, muscle, pancreas, small intestine, and kidney (Figure 2.2). 
2.2 AGING PHENOTYPES IN COX2 TRANSGENIC MICE 
Tamoxifen-injected COX2 transgenic mice appeared normal until the age of 20 
weeks, when we first noticed an unkempt and greasy hair coat (Figure 2.3). Reduced 
subcutaneous fat is one of the markers for aged skin (Tyner, Venkatachalam et al. 2002). 
The analysis of hematoxylin and eosin (H&E)-stained sections of skin revealed a 
reduction in the subcutaneous fat in 20-week-old COX2 transgenic mice when compared 
to the skin in tamoxifen-injected control littermates (Figure 5 A-D, n=12). Additionally, 
hyperplasia of the sebaceous gland (Figure 2.4 E-F) was observed in COX2 transgenic 
skin, as is also observed in aged human skin (Kumar, Barton et al. 1988, Zouboulis and 
Boschnakow 2001), and in the skin of XPD mutant mice, which exhibit premature aging 
phenotypes (de Boer, Andressoo et al. 2002). 
Hair regrowth also declines as a function of age in mice (Harrison and Archer 
1988), and is reduced in other mouse models of aging (Tyner, Venkatachalam et al. 2002, 
Li, Zhao et al. 2013). Thus, a hair re-growth assay was performed to investigate the 
impact of COX2 on hair growth. In mouse skin, coordinated hair regeneration occurs in a 
wave-like pattern across the skin surface. However, in old mice, waves of hair growth 
slow down, or hair cycle domains fragment into smaller domains, resulting in patchy hair 
growth (Chen, Murray et al. 2014). As shown in Figure 2.5, delayed or patchy re-growth 
of hair was observed in all COX2 transgenic mice, whereas the age-matched control mice 
exhibited normal hair re-growth 20-days after removal of hairs. 
12 
Tamoxifen-induced COX2 transgenic mice exhibited other signs of aging. The 
lifespan of COX2 transgenic mice was significantly reduced compared to that of control 
mice (Figure 2.6 A). Studies have shown that there is a reduction in muscle fiber size 
with increasing age (Welle 2002). As shown in Figure 2.6 B and C, the size of the muscle 
fiber in the hind leg of COX2 transgenic mice was reduced compared to that in control 
littermates (n=5). The increase in heart weight is normally found in the aging human 
heart (Waller 1988, Melissari, Balbi et al. 1991). The heart weight relative to body weight 
was increased in COX2 transgenic mice (Figure 2.6 D, n=9) compared to that in control 
littermates. We also performed quantitative assessments of body composition with X-ray 
densitometry of the whole mouse. The fat content was reduced in COX2 transgenic mice 
compared to control littermates, consistent with the results from histological analysis of 
subcutaneous fat (Figure 2.6 E, n=5). COX2 transgenic mice also exhibited changes in 
peripheral blood composition. White blood cell counts in transgenic animals were 
significantly lower than those in control littermates (Figure 2.6 F). In addition, some 
COX2 transgenic mice developed ocular abnormalities such as opaque eyes and 
blindness (Figure 2.6 G). 
Female fertility decreases with age, and males develop an age-associated decline 
in sperm count (Pal and Santoro 2003). We set up matings between 10 COX2 transgenic 
males (12 ~ 23 weeks old) and 10 wild-type females. However, none of the wild-type 
females became pregnant after two months of being housed together. Testes of the COX2 
transgenic males were generally smaller than wild-type testes (Figure 2.7 A). Histological 
analysis of transgenic testes revealed the absence or reduced number of mature 
spermatozoa (Figure 2.7 B). We also set up matings between 12 COX2 transgenic 
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females and 12 wild-type males. However, only one out of the 12 transgenic females 
became pregnant. Histological analysis showed that the ovaries of 40-week-old COX2 
transgenic mice were atrophic with minimal follicles and compensatory interstitial 
hyperplasia, which suggests that these ovaries have been exhausted (Figure 2.8 A-C). 
Additionally, ovarian bursal cysts were often observed in COX2 transgenic female mice 
(Figure 9 D and E), which is commonly observed in aged mice (Dixon, Alison et al. 
2014). 
The incidence and severity of pancreatitis increases in elderly population 
(Browder, Patterson et al. 1993, Fagenholz, Castillo et al. 2007, Frey, Zhou et al. 2007). 
Colby et al. have shown that bovine keratin 5 promoter-driven expression of COX2 in 
dysplastic changes in the pancreas (Colby, Klein et al. 2008). Consistent with their 
findings, pancreata of COX2 transgenic mice exhibited phenotypes similar to chronic 
pancreatitis such as the loss of the pancreatic acini, the increase of the metaplastic 
pancreatic ducts with dysplastic changes, periductal fibrosis, and mononuclear 
inflammatory cell infiltration in the highly vascularized fibrotic stroma (Figure 2.9). 
Hyperplasia of the Langerhans islets was also noticed, which is often associated with age 
in mice (Brunnert, Herron et al. 1990). 
2.3 INCREASED SENESCENCE IN COX2 TRANSGENIC MICE 
Cellular senescence has been proposed to contribute to aging phenotypes and/or 
the development of certain age-related diseases (Campisi 2003). The number of senescent 
cells increases with age in mammalian tissues (Campisi 2005), and such cells have been 
found at sites of age-related pathologies such as osteoarthritis and atherosclerosis (Price, 
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Waters et al. 2002, Matthews, Gorenne et al. 2006). Immunohistochemical analysis of 
p16, an indicator of senescence, revealed that the number of p16-positive cells was 
increased in the pancreata of COX2 transgenic mice compared to that in pancreata of 
control littermates (Figure 2.10 A and B). In addition, immunohistochemical analysis of 
phospho-H2AX, a marker of DNA damage, showed that the number of phospho-H2AX-
positive cells was increased in the pancreata of transgenic mice (Figure 2.10 C and D). 
Similarly, Western blot analysis showed increased levels of p16 and phospho-H2AX in 
transgenic pancreas (Figure 2.11). Increase in the number of phospho-H2AXpositive cells 
was also observed in the skin of COX2 transgenic mice (Figure 2.10 E and F). 
To determine whether increased COX2 expression is associated with the 
increased cellular senescence, we performed senescence-associated beta-galactosidase 
(SA-β-gal) staining (Debacq-Chainiaux, Erusalimsky et al. 2009) using adult mouse lung 
fibroblasts isolated from control and COX2 transgenic mice. The isolated fibroblasts 
were incubated with 1μM of 4-hydroxytamoxifen to induce COX2 expression. As shown 
in Figure 2.12 A-C, the number of SA-β-gal-positive cells was increased in COX2 
transgenic fibroblasts compared to that in control fibroblasts. However, treatment of 
COX2 transgenic fibroblasts with NS-398, a COX2 specific inhibitor, significantly 
reduced the number of SA-β-gal-positive cells (Figure 13 A and B). These results suggest 
that premature aging phenotypes may be linked to COX2-mediated induction of cellular 
senescence. 
In summary, post-natal expression of COX2 led to a panel of aging-related 
phenotypes, and additionally, adult mouse lung fibroblasts from COX2 transgenic mice 
exhibited increased SA-β-gal activity. These results suggest that the increased COX2 
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expression has an impact on the aging process and that modulation of COX2 and its 
downstream signaling may be an approach for the intervention of age-related disorders.
 16 
Figure 2.1 Generation of COX2 transgenic mouse. Diagram of CAG/CAT/hCOX2 
construct is shown. 
 17 
 
Figure 2.2 Expression of COX2 in various tissues of tamoxifen-inducible COX2 
transgenic mouse. COX2 expression was induced in 5-week-old (CATflCOX2:Rosa-
Cre ERT2) mice by intra-peritoneal injections of tamoxifen. Paraffin-embedded 
sections of 20-week-old COX2 transgenic mice were stained for COX2 using a human 
COX2-specific antibody. The tissues shown are heart (A), kidney (B), skeletal muscle 
(C), pancreas (D), small intestine (E), and skin (F). Scale bar=100µm 
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Figure 2.3 Appearance of control and transgenic mice. Representative photographs of 
general appearance of 20-week-old control (CT) and COX2 transgenic (TG) mice. 
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Figure 2.4 COX2 transgenic expression decreased subcutaneous fat. Cross-sections of 
dorsal skin from 20 weeks-old control (A, C and E) and COX2 transgenic (B, D, and 
F) littermate. Epidermis (E), dermis (D), adipose under the dermis (A), and muscle 
(M) are indicated. The COX2 transgenic skin exhibits sebaceous gland hyperplasia 
and a decrease in subcutaneous fat and muscle. (G) Quantification of the thickness of 
subcutaneous fat in control and COX2 transgenic mice (***: p<0.001). 
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Figure 2.5 COX2 transgenic expression slowed hair growth rate. A representative 
photo of 20 weeks-old COX2 transgenic and age-matched control male mice at 20d 
after hair removal on a dorsal area, and quantification of hair re-growth in control and 
COX2 transgenic mice (***: p<0.001) 
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Figure 2.6 COX2 transgenic expression resulted in various aging phenotypes. (A) 
Longevity in control (n=23) and COX2 transgenic (n=25) mice. (B) H&E stained 
sections of hind leg skeletal muscle from 22-week-old control (CT) and COX2 
transgenic (TG) female littermates. Cross sections of the extensor digitorum longus 
(EDL) muscle are shown. Scale bar=100µm. (C) Frequency distribution of skeletal 
muscle fiber cross-sectional area (CSA) between control (CT) and COX2 transgenic 
(TG) mice. (D) Heart weight/body weight (HW/BW) ratios in tamoxifen-induced 
control (CT) and COX2 transgenic (TG) male littermates at the age of 22 weeks. 
HW/BW ratios in COX2 transgenic mice were significantly higher than those in 
control mice (paired t-test, p<0.001). (E) Quantitative assessment of fat content by X-
ray densitometry of control (CT) and transgenic (TG) mice (n=5). (F) White blood 
cell (WBC) counts in tamoxifen-induced control (CT) and COX2 transgenic 
littermates (paired t-test, *: p<0.05, **: p<0.01, n=4). (G) The opacity of cornea 
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Figure 2.7 Male fertility decreased after COX2 transgenic expression. (A) Testis from 
25 weeks-old control (CT) and COX2 transgenic (TG) male littermate at the age of 25 
weeks. The size of the testis is reduced in COX2 transgenic mice (n=3). (B) Cross-
sections of testis of control (CT) and COX2 transgenic (TG) mice at 22 weeks. While 
control testis the contains the sperm (arrows), the sperms were not observed in COX2 
transgenic testis. 
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Figure 2.8 Female fertility decreased after COX2 transgenic expression. H&E staining 
of ovarian sections from 40-week-old (A) control (CT) and (B) COX2 transgenic mice 
(magnification x5). (C) Higher magnification (x10) view of the ovary shown in (B). 
(D) The ovary from 22-week-old COX2 transgenic mouse showing a cystic structure 
filled with a clear fluid (arrow). (E) H&E stained bursal cyst in COX2 transgenic 
mouse. The cyst contains pale eosinophilic proteinaceous material. Scale bar=100μm. 
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Figure 2.9 H&E stained sections of pancreas from COX2 transgenic mice (TG) 
showing the loss of the pancreatic acini, the increase of the metaplastic pancreatic 
ducts with dysplastic changes, peri‐ductal fibrosis, and mononuclear inflammatory 
cell infiltration in the highly vascularized fibrotic stroma. Hyperplasia of the 
Langerhans islets was also noticed. Scale bar=100μm. 
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Figure 2.10 (A) and (B) Immunohistochemical staining of p16 in the pancreata from 
25-week-old control and COX2 transgenic littermates (magnification x20). (C) and 
(D) Immunohistochemical staining of phosphor-H2AX in the pancreata from 23-
week-old control and COX2 transgenic littermates (magnification x20). (E) and (F) 
Immunohistochemical staining of phosphor-H2AX in the skin from 25-week-old 
control and COX2 transgenic littermates (magnification x20). Scale bar=100µm. 
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Figure 2.11 Western blot analysis of COX2, phosphor-H2AX, and p16 in pancreas of 
control (CT) and COX2 transgenic (TG) mice. 
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Figure 2.12 COX2 transgenic expression increased cellular senescence level. (A) and 
(B) Adult mouse lung fibroblasts from control and COX2 transgenic mice were 
incubated with 4-hydroxytamoxifen for 24 hours to induce COX2 expression in 
transgenic fibroblasts. The cells were cultured in the regular culture medium for 48 
hours before SA-β-Gal staining. Representative pictures from 3 independent 
experiments are shown. Quantification results are shown in (C). 
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Figure 2.13 (A) Adult mouse lung fibroblasts from control and COX2 transgenic mice 
were incubated with 4-hydroxytamoxifen for 24 hours to induce COX2 expression in 
transgenic fibroblasts. The cells were cultured in the regular culture media containing 
DMSO or 10µM NS398 for 72 hours before SA-β-gal staining. Quantification results 
are shown in (B). 
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CHAPTER 3 
DEVELOPMENT OF A MOUSE MODEL OF CHEMOTHERAPY-
INDUCED AGING 
3.1 ANALYSIS OF AGING PHENOTYPES IN DOX-TREATED MICE 
DOX is frequently used in the treatment of childhood cancer. We used DOX as a 
chemotherapeutic agent in our studies because DOX has been shown to induce 
senescence in both humans and mice (Sanoff, Deal et al. 2014, Demaria, O'Leary et al. 
2016, Baar, Brandt et al. 2017), and because anthracyclines including DOX have been 
widely used to treat children with cancer in the past, suggesting that many current 
survivors of childhood cancer may have received DOX treatment. Mouse models have 
been used to study DOX-induced chronic or acute cardiotoxicity (Delgado, Nawar et al. 
2004, Neilan, Blake et al. 2007, Yalcin, Oruc et al. 2010, Kim, Kim et al. 2015). 
However, these models used adult mice (6~12 weeks old), and DOX-treated mice often 
die due to complications in cardiac function. To investigate the late effects of 
chemotherapy, we developed a new mouse model in current study. 
Protocols for DOX treatment for both adults and children use a maximum 
cumulative dose of 450-550 mg/m2 (Harake, Franco et al. 2012), equal to 18-22 mg/kg. 
Childhood malignancy patients could get mean cumulative DOX dose of 406mg/m2 
(Lipshultz, Lipsitz et al. 2002), equal to 16.24mg/kg. Several chemotherapy studies in 
rats used a cumulative dose of 15mg/kg body weight of DOX given over six equal 
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injections (Harake, Franco et al. 2012). We chose a relatively low DOX dose intensity, 
10mg/kg cumulative dose, and treated C57BL/6 mouse according to Figure 3.1. DOX-
treated mice exhibited reduced body weight (Figure 3.2 A and B), compared to PBS-
injected littermates. In addition, DOX-treated mice showed decreased inguinal fat weight 
(Figure 3.3 A and B) and epididymal fat weight (Figure 3.3 C and D). Additionally, 
various essential organs also exhibited reduced weight, like liver (Figure 3.4 A and B), 
spleen (Figure 3.4 C and D), pancreas (Figure 3.5 E and F), and lung (Figure G and H), 
indicating general decline in body function after DOX treatment. Some DOX-treated 
mice also exhibited pronounced lordokyphosis (Figure 3.2 C), another sign of aging. 
To analyze the effect of DOX on reproduction capacity, 4 DOX-treated male mice 
were kept in the same cage with 4 female control mice of the same age, and none of these 
female mice were found pregnant. Additionally, when 4 female DOX-treated mice were 
set in the same cage with 4 male control mice of the same age, only 1 out of these 4 
females were found pregnant, indicating that DOX treatment causes a decline in 
reproductive capacity. Together, these observations suggest that treatment of juvenile 
mice with DOX may cause early aging. 
3.2 HISTOLOGICAL ANALYSIS OF TISSUE AGING 
To further analyze the effect of DOX on tissue aging in vivo, various tissue 
samples from both control and DOX-treated mice were fixed with 10% formaldehyde. 
Samples were then embedded into paraffin blocks and sectioned into 5µm sections. 
Sections were stained with hematoxylin and eosin for histological analysis. 
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Hematoxylin and eosin (H&E) staining of skin sections showed decreased 
subcutaneous fat (Figure 3.5), and muscle fiber size (Figure 3.6) in DOX-treated mice, 
compared to control littermates. DOX-treated mice also had decreased testicle weight 
(Figure 3.7), and reduced sperm population in the testicle (Figure 3.8), confirming the 
reduced reproductive capacity under DOX influence. 
3.3 ANALYSIS OF CELLULAR SENESCENCE AFTER DOX TREATMENT 
Accumulation of senescent cells is associated with aging (Campisi 2013), and 
DOX is known to induce cellular senescence (Soleimani, Heytens et al. 2011). As shown 
in Figure 3.9, treatment of WI38, a normal human fibroblast cell line, with DOX, 
increased the number of SA-β-gal positive cells (increased by more than 6 folds from 
9.7% to 59.4%), confirming that this chemotherapeutic agent induces cellular senescence. 
DOX-treated mice, along with control littermates, were sacrificed and various 
tissues were harvested and embedded in Embedding Medium for Frozen Tissue 
Specimens to ensure Optimal Cutting Temperature (O.C.T) Compound. Cryosections 
were made from these samples, and SA-β-gal staining assay was performed to check the 
cellular senescence level in vivo. Increased number of SA-β-gal positive cells was 
observed in liver (Figure 3.10 A), spleen (Figure 3.10 B), pancreas (Figure 3.10 C), and 
lung (Figure 3.10 D) in DOX-treated mice, comparing to their control littermate, 
indicating that DOX causes cellular senescence not only in vitro (Figure 3.9), but also in 
vivo. 
In the liver of DOX-treated mice, the senescent cells accumulated in liver 
parenchyma (Figure 3.10 A), which is made up of hepatocytes that filter blood to remove 
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toxins. The liver is a vital organ of detoxification, and increased cellular senescence level 
in liver parenchyma suggests that DOX might damage the detoxification function of the 
liver, which could reduce the mouse resistance to DOX toxicity, assisting in the 
occurrence of cellular senescence in other organs across the body. The SA-β-gal positive 
senescent cells were accumulated in exocrine pancreas (Figure 3.10 C) and in cells 
forming alveoli and bronchus in the lung (Figure 3.10 D), indicating that DOX treatment 
might impair digestive and respiratory systems. 
DOX may also damage the immune system. There are two main compartments in 
the spleen, the white pulp and the red pulp. The white pulp contains lymphocytes and 
initiates immune responses to blood-borne antigens, while the red pulp is a blood filter 
that removes foreign material and damaged and effete erythrocytes, and is also a storage 
place for iron, erythrocytes, and platelets. In rodents, it also serves as the site of 
hematopoiesis (Cesta 2006). It has been reported that red pulp is also a reservoir of 
monocytes, which upon moving into injured tissues, turn into dendritic cells and 
macrophages to participate in immune response like inflammation regulation and wound 
healing (Swirski, Nahrendorf et al. 2009). In our study, SA-β-gal staining was mostly 
observed in red pulp (Figure 3.10 B), suggesting that DOX might impair the mouse 
immune response to tissue damage, so that senescent cells can accumulate and stay 
longer, and in this way, contributes to the development of early aging phenotypes. 
Markers of senescent cells include high expression of cell cycle regulator (p16 
and p21), SASP factors like interleukin-6 (IL6), and an increase in cellular senescent-
associated β-galactosidase (SA-β-gal) activity, among others (Kirkland, Tchkonia et al. 
2017). None of these markers are fully sensitive or specific, so testing more than one 
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marker is needed to draw conclusions about the senescence induction effect of DOX. 
Based on this, we also tested the mRNA level of multiple cellular senescence markers in 
various mouse tissues. The p16 mRNA level was elevated in liver (3.11 A), spleen (3.11 
B), and lung (3.11 C), while p21 mRNA level was increased in spleen (3.11 D), liver 
(3.11 E), and lung (3.11 F). Besides, we also detected significant increase of IL6 mRNA 
level in liver (3.12 A), tibialis anterior (3.12 B), gastrocnemius (3.12 C), spleen (3.12 D), 
inguinal fat (3.12 E) and skin (3.12 F), confirming that DOX treatment could induce 
general cellular senescence response across the entire body. 
In summary, we have established a novel chemically-induced mouse model to 
study the cellular senescence, early aging, and late effect of chemotherapy. With this 
model, we demonstrated that DOX, a chemotherapeutic agent, induces cellular 
senescence and aging phenotypes.  
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Figure 3.1 Mouse DOX treatment procedure. Pharmacological treatment procedure of 
C57BL/6 with DOX. 2.5 mg/kg DOX was injected into C57BL/6 mouse when the 
mouse was 2, 3, 4, and 5-week-old. Various tissues were harvested when the mouse 
was 16-18-week-old. 
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Figure 3.2 DOX treatment decreased mouse body weight. (A) A representative 
photograph of mice after PBS and DX treatment. (B) Body weight curves of PBS and 
DX-treated male mice (n=6). (C) A representative photograph of skinned DX-treated 
mouse that exhibits pronounced lordokyphosis, along with its littermate control. 
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Figure 3.3 DOX treatment decreased inguinal fat weight/body weight ratio and 
epididymal fat weight/body weight ratio in mice. (A) A representative photograph of 
mouse inguinal fats (Arrows) after PBS (Control) and DOX treatment. (B) Inguinal fat 
weight/body weight ratio decreased after DOX treatment (n=5). (C) A representative 
photograph of mouse epididymal fats (Arrows) after PBS (Control) and DOX 
treatment. (D) Epididymal fat weight/body weight ratio decreased after DOX 
treatment (n=5). 
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Figure 3.4 DOX treatment decreased organs weight/body weight ratio in mice. (A) 
Liver weight/body weight ratio decreased after DOX treatment (n=5). (B) A 
representative photograph of mouse livers after PBS (Control) and DOX treatment. 
(C) Spleen weight/body weight ratio decreased after DOX treatment (n=5). (D) A 
representative photograph of mouse spleens after PBS(Control) and DOX treatment. 
(E) Pancreas weight/body weight ratio decreased after DOX treatment (n=5). (F) A 
representative photograph of mouse pancreases after PBS (Control) and DOX 
treatment. (G) Lung weight/body weight ratio decreased after DOX treatment (n=5). 
(H) A representative photograph of mouse lungs after PBS (Control) and DOX 
treatment. 
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Figure 3.5 DOX treatment decreased subcutaneous fat in mice. (A) Representative 
photographs of skin H&E-stained sections after PBS (Control) and DOX treatment. 
(B) Subcutaneous fat decreased after DOX treatment (n=7). The skin sample was 
embedded into paraffin block and sectioned into 5µm sections. Sections were stained 
with hematoxylin and eosin after 1h baking at 60°C within hybridization oven. 
Subcutaneous fat width was measured with ImageJ. 
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Figure 3.6 DOX treatment decreased muscle fiber size. (A) H&E stained sections of 
hind leg skeletal muscle from control and DX-treated male littermate. Cross sections 
of the extensor digitorium longus (EDL) muscle are shown. (B) Frequency 
distribution of skeletal muscle fiber cross-sectional area (CSA) between control and 
DOX-treated mice. 
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Figure 3.7 DOX treatment decreased testicle weight/body weight ratio in mice. (A) 
Representative photograph of testicles after PBS and DOX treatment; (B) Testicle 
weight/body weight ratio decreased after DOX treatment (n=4). 
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Figure 3.8 DOX treatment decreased sperm population in mice. Representative 
photographs of testicle H&E-stained sections after PBS (Control) and DOX treatment. 
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Figure 3.9 DOX increases the percentage of senescent WI38 cells. WI38 cells were 
treated with either DMSO (Control) or 1mM DOX for 2h, and then SA-β-gal staining 
assay was performed to check cellular senescence. (A) Representative photographs of 
WI38 cells after vehicle (Control) and DOX treatment. (B) SA-β-gal-positive cell 
number increased after DOX treatment. 
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Figure 3.10 DOX induced cellular senescence in vivo. DOX caused cellular 
senescence in liver (A), spleen (B), pancreas (C), and lung (D) in vivo. R: Red pulp; 
W: White pulp. 
 
 44 
 
Figure 3.11 DOX caused cellular senescence markers, p16 and p21, in mouse tissues. 
p16 mRNA level was increased after DOX treatment in liver (A), spleen (B) and lung 
(C). p21 mRNA level was increased after DOX treatment in spleen (D), liver (E), and 
lung (F). 
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Figure 3.12 DOX caused cellular senescence markers, IL6, in mouse tissues. of liver 
(A), tibialis anterior (B), gastrocnemius (C), spleen (D), inguinal fat (E), and skin (F). 
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CHAPTER 4 
ROLE OF COX2 IN CHEMOTHERAPY-INDUCED CELLULAR 
SENESCENCE AND AGING 
4.1 ANALYSIS OF COX2 EXPRESSION IN TISSUES OF DOX-TREATED MICE 
It has been reported that chemotherapeutic agents induce COX2 expression 
(Altorki, Port et al. 2005, Brown and DuBois 2005, Hwang, Ha et al. 2005, Logan, 
Gibson et al. 2007). Since inducible COX2 expression in adult mice accelerated aging 
phenotypes, we hypothesized that COX2 contributes to the aging phenotypes in DOX-
treated mice. To test this hypothesis, protein lysates were made from the tissues of the 
mice treated with either PBS or DOX, and western blotting was performed to check the 
COX2 protein level. Increased COX2 expression was observed in skin, liver, inguinal fat, 
and thymus of DOX-treated mice (Figure 4.1), suggesting that DOX-induced cellular 
senescence and aging phenotypes may be mediated by COX2. 
4.2 IN VITRO ANALYSIS OF THE EFFECT OF COX2 DELETION ON 
CHEMOTHERAPY-INDUCED SENESCENCE 
As previously mentioned, chemotherapy is known to induce COX2 expression. 
To analyze the role of COX2 in DOX-induced cellular senescence, MEFs were isolated 
from COX2 knockout and WT embryos (Figure 4.2). Wild type and COX2 KO MEFs 
were then treated by 0.2µM DOX for 24h to induce cellular senescence. As shown in 
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Figure 4.3, SA-β-gal staining showed that the number of senescent cells was significantly 
reduced in COX2 KO MEFs comparing to that in WT MEFs, suggesting that COX2 is 
involved in DOX-induced cellular senescence. 
4.3 IN VIVO ANALYSIS OF P53 AND P21 IN DOX-TREATED MICE 
Increased p53 expression was observed in COX2 transgenic mouse embryos 
(Shim, Foley et al. 2010). In addition, we recently have demonstrated that COX2 
regulates DNA damage-induced expression of p53 through modulation of oxidative stress 
(Kim and Shim 2016). Additionally, p53 is known to play an important role in cellular 
senescence and aging (Collado, Blasco et al. 2007), and targeting p53 signaling has been 
reported as a feasible strategy to induce apoptosis of senescent cells (Baar, Brandt et al. 
2017). Therefore, we hypothesized that DOX mediates cellular senescence and aging 
phenotypes through COX2-p53 signaling. 
To examine whether p53 expression is altered in COX2 transgenic mice, we 
assessed the levels of p53 in the tissues of control and COX2 transgenic mice. Western 
blot analysis revealed that expression of p53 was increased in various tissue lysates 
(pancreas, skin, and muscle) of COX2 transgenic mice (Figure 4.4). 
To determine whether p53 is involved in DOX-induced senescence and aging, 
protein lysates were made from the various tissue of mouse treated with either DOX or 
PBS (Control), and subjected to Western blot analysis for p53 and p21. p21 is a cyclin-
dependent kinase inhibitor that is capable of inhibiting all cyclin/CDK complexes and is a 
downstream target of p53 signaling. As shown in Figure 4.5, both p53 and p21 protein 
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levels were increased in the tissues of DOX-treated mice, including liver, skin, spleen, 
thymus, testicle, and lung, indicating that DOX-treatment also induces p53 signaling. 
In addition, wild type and COX2 KO MEFs, isolated from WT and COX2 KO 
embryos, were treated with 0.2µM DOX for 24h to induce cellular senescence. The 
protein level of p53 and p21 were analyzed with western blotting. As shown in Figure 
4.6, COX2 knockout could decrease DOX-induced p53 and p21 level.  This encouraged 
us to investigate how COX2 is involved in DOX-induced cellular senescence and aging. 
To future determine whether COX2 inhibition affects p53 levels, WI38 cells were 
treated with DOX in the presence of either non-selective COX inhibitors (aspirin and 
piroxicam), or selective COX2 inhibitors (DuP-697 and celecoxib). As shown in Figure 
4.7, the DOX-induced increase in p53 levels was decreased after treatment with either 
non-selective or selective COX2 inhibitors. These results suggest that COX2 may 
regulate cellular senescence and/or aging through modulation of p53 signaling. 
4.4 THE EFFECT OF COX INHIBITOR ON AGING-PHENOTYPES IN DOX-
TREATED MICE 
Non-steroidal anti-inflammatory drugs (NSAIDs) are believed to exert their 
effects by inhibiting prostaglandin synthesis through COX inhibition. Among these 
NSAIDs, aspirin has been used for more than one hundred years (Hawkey 1999). In 
DOX-treated mice, we observed not only aging phenotypes, but also increased COX2 
level. This led us to wonder if COX2 plays a critical role in this DOX-induced aging 
process, and thus if inhibiting COX2 could recover DOX-induced aging phenotypes. To 
test this, DOX- or PBS-treated mice were fed aspirin according to Figure 4.8. 
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As expected, DOX-treated mice showed reduced body weight. However, aspirin 
treatment recovered body weight in DOX-treated mice (Figure 4.9 A) In addition, the 
white blood cell (WBC) loss caused by DOX (Figure 4.9 B), which is also an indicator of 
aging (de Labry, Campion et al. 1990), was also recovered by aspirin feeding. These 
results suggest that COX may play a role in DOX-induced aging phenotypes. 
Besides these, other aging phenotypes observed in DOX-treated mice were also 
recovered after aspirin treatment, like decreased inguinal fat weight (Figure 4.10), 
decreased epididymal fat weight (Figure 4.11), and decreased sperm population (Figure 
4.12). Decreased weight of other tissues, like brown adipose tissue, testicle and lung, was 
recovered too (Figure 4.13). Histological analysis of tissue sections revealed recovered 
level of subcutaneous fat loss (Figure 4.14), muscle fiber size decrease (Figure 4.15), 
inguinal adipocyte size decrease (Figure 4.16) and brain neuron necrosis (Figure 4.17). 
Additionally, the DOX-induced inguinal fat inflammation, as shown by necrosis and 
immune cell infiltration (Figure 4.16), was also down-regulated with aspirin treatment. 
These data indicate that COX inhibition with aspirin could reverse DOX-induced aging 
phenotypes. 
4.5 THE EFFECT OF ASPIRIN ON DOX-INDUCED CELLULAR SENESCENCE IN 
VIVO 
The fact that aspirin recovered DOX-caused aging phenotypes encouraged us to 
test if aspirin could also recover the in vivo cellular senescence induced by DOX. SA-β-
gal in vivo staining was performed with cryosections of liver, spleen, pancreas, and lung, 
from which we have already proved that DOX induces cellular senescence. Figure 4.18 
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shows that aspirin significantly decreased the number of senescent cells in all these four 
organs. Indeed, DOX-elevated levels of senescent markers, p16 and IL6, were also 
significantly decreased with aspirin treatment in tissues like liver, inguinal fat, and spleen 
(Figure 4.19). This result indicates that COX activity may play a role in DOX-induced 
cellular senescence. 
4.6 COX AS A TARGET TO REVERSE DOX-INDUCED AGING 
Aspirin has also been reported with functions independent of COX signaling. 
Aspirin diffuses from mitochondria intermembrane space as a proton carrier into the 
mitochondrial matrix, from where it ionizes to release protons. In this way, it acts as a 
competitor to ATP synthase, uncoupling oxidative phosphorylation in cartilaginous and 
hepatic mitochondria to cause hyperthermia due to large amount of released heat from 
electron transport chain, as opposed to the expected antipyretic action (Somasundaram, 
Sigthorsson et al. 2000). Also, aspirin could promote NO radical formation, resulting in 
reduced leukocyte adhesion and further decreased inflammation level (Paul-Clark, Van 
Cao et al. 2004). Additionally, it might also act through NF-κB (McCarty and Block 
2006), which’s pathway has long been considered a prototypical proinflammatory 
signaling pathway based on the role of NF-κB in the expression of proinflammatory 
genes including cytokines, chemokines, and adhesion molecules (Lawrence 2009). 
To confirm that the aging rescue effect of aspirin comes from its COX inhibition 
activity, we tried to use COX2 knockout mouse (COX2 KO) to repeat this experiment. 
COX1 and COX2 are key enzymes in prostaglandin biosynthesis (Langenbach, Morham 
et al. 1995). While homozygous COX1 mutant mice exhibited decreased inflammatory 
 51 
response and reduced fertility (Langenbach, Morham et al. 1995), possibly due to 
decreased platelet aggregation, delayed parturition and neonatal death (Gross, Imamura et 
al. 1998), absence of COX2 resulted in female infertility because of severe renal 
pathology (Morham, Langenbach et al. 1995) and defective decidualization (Lim, Paria et 
al. 1997). COX2 inhibition in homozygous mice resulted in complete reproductive failure 
(Reese, Zhao et al. 2001). Based on these information, we suspected that the impaired 
fertility might come from reduced cellular senescence, since senescence has beneficial 
effects in embryonic development and wound healing (McCulloch, Litherland et al. 
2017), while our study suggests that COX activity is required to achieve senescence. 
Besides, because of defective fertility of COX1 and/or COX2 mutant mice, we decided to 
use an inducible COX2 KO mouse line in present study. 
The inducible COX2 KO mouse was a kind gift from Dr. FitzGerald lab at the 
University of Pennsylvania (Wang, Patel et al. 2009). In this mouse line, exons 6, 7, and 
8, which are critical for enzyme activity, were flanked by 2 directly repeated loxP sites 
inserted into the corresponding introns. Then, the mice were crossed into merCremer 
mice under the α-myosin heavy chain promoter to permit tamoxifen-dependent deletion 
of COX2 (Wang, Patel et al. 2009). DOX and tamoxifen treatment was according to 
Figure 4.20. Briefly, 4 weeks after DOX treatment, mice were treated with tamoxifen to 
induce COX2 knockout. The mouse phenotypes were analyzed 6 weeks after COX2 
deletion. 
Interestingly, COX2 deletion recused DOX-induced body weight loss (Figure 
4.21 A). Monocyte is a type of white blood cell, and if functional parameters are 
assessed, its number may approach 20% of the total white blood cell count (Zucker-
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Franklin 1974). The DOX-decreased monocyte population was also recovered by 
tamoxifen treatment (Figure 4.22 A). These indicate that the DOX-induced aging 
phenotypes can be at least partially recused by COX2 deletion, and the aging-rescuing 
effect of aspirin indeed came from its COX inhibition activity. 
Indeed, when aspirin was replaced by SC-236 (Figure 20), an selective COX2 
inhibitor (Deleo, Hashizume et al. 2000), the same phenomenon could also be observed, 
like rescued body weight and monocyte population (Figure 21 B and Figure 22 B), 
further confirming that the aging-rescuing effect of aspirin we detected before was due to 
COX inhibition. 
Notably, compared to aspirin (Figure 4.9), both COX2 KO and SC-236 group had 
less body weight gain, although this might come from different administration methods 
between aspirin and tamoxifen/SC-236. While aspirin was dissolved in mouse-feeding 
water, which was less harmful, both tamoxifen and SC-236 were administrated with 
intraperitoneal injection, which could cause mice more stress. Additionally, tamoxifen 
itself is a known toxin, inducing cell apoptosis and necroptosis (Kim, Amarnani et al. 
2014),  and mouse atrophy (Huh, Khurana et al. 2012). SC-236 was first dissolved in 
DMSO and then water, making the final 5% DMSO solution, and DMSO was also known 
to cause cell damage (Sperling and Larsen 1979), caspase-3 independent neuronal death 
(Galvao, Davis et al. 2014), and apoptosis(Hanslick, Lau et al. 2009). 
4.7 COX INHIBITORS AS NEW GENERATION OF SENOLYTIC DRUGS 
Back in 2011, the senescence marker p16 was used to design a novel transgene 
INK-ATTAC, for inducible elimination of p16 positive cells upon administration of 
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AP20187 (Baker, Wijshake et al. 2011). Surprisingly, life-long removal of p16-
expressing cells delayed the onset of aging phenotypes like decreased muscle fiber size 
and adipose tissue loss, and even attenuated progression of already established age-
related disorders like decreased adipocyte cell size and subdermal adipose layer 
thickness. Remarkably, 8-month clearance of p16-expressing cell yielded no any 
detectable overtly negative side effects (Baker, Wijshake et al. 2011). This encouraged 
the usage of senescent cells as target of drugs which aimed at tissue rejuvenation and 
aging prevention. 
Up to date, several such drugs, which were called senolytic drugs, have been 
developed, like quercetin, dasatinib (Zhu, Tchkonia et al. 2016), ABT263 (Chang, Wang 
et al. 2016), ABT737 (Yosef, Pilpel et al. 2016), FOXO4-DRI (Baar, Brandt et al. 2017). 
But they were either non-specific or not FDA-approved, which prevented their quick 
therapeutic use. NASIDs are the most frequently consumed drugs worldwide (Frolich 
1997), and most of them are already FDA-approved. What’s more, long term usage of 
NASIDs like aspirin has even been reported with positive effects like prolonged lifespan 
(Vane and Botting 2003), indicating that NASIDs’ long term usage is acceptable and 
safe. Since the administration of COX inhibitors like aspirin partially recovered aging 
phenotypes through elimination of senescent cells, we wondered that if NASIDs could be 
developed as a new generation of senolytic drugs. 
To test this, WI38 human fibroblast cells were first treated with DOX to induce 
senescence, and then various concentrations of aspirin and sulindac, another COX 
inhibitor known to inhibit both COX1 and COX2 (Oshima, Dinchuk et al. 1996), were 
applied. As expected, the viability of senescent WI38 cells were sharply decreased in a 
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dose-dependent manner by both sulindac and aspirin (Figure 4.23), indicating that indeed 
NASIDs have senolytic potential. 
In order to test if the clearance effect of NASIDs is senescent cell-specific, SA-β-
gal assay was performed. As cell proliferation capability is reduced and cell growth 
arrested, fibroblasts acquire a drastically different morphology compared to control cells, 
appearing considerably larger in size, flatter, less contrasted, and more adhesive to the 
per-nuclear area (Anastasia, Sampaolesi et al. 2006, Piccoli, Palazzolo et al. 2012). While 
fibroblasts in the control group were flatter and less contrasted, indicating reduced 
proliferation capability and cell growth arrest due to DOX treatment, the remaining 
fibroblasts in NASID groups, especially 5mM aspirin, exhibited spindle morphology 
characteristic of low cumulative population doubling proliferating fibroblasts (Walters, 
Deneka-Hannemann et al. 2016), suggesting increased activity and growth (Figure 4.24). 
While senescent cell viability was decreased (Figure 4.24), senescent cell population 
percentage was also significantly decreased in total cell population (Figure 4.25), after 
the administration of either sulindac or aspirin, indicating that the COX inhibitors 
targeted senescent cell specifically. 
Cellular senescence requires two factors: cell cycle arrest caused by p53 and 
simultaneous activation of the mTOR signaling (Korotchkina, Leontieva et al. 2010). p70 
can be directly phosphorylated and activated by mTOR  (Hara, Yonezawa et al. 1998, 
Isotani, Hara et al. 1999), which has been reported recently as critical to the survival of 
senescent cells (Korotchkina, Leontieva et al. 2010). pan-mTOR inhibition by TOR-
specific ATP mimetic AZD8055 was recently found to have cellular senescence reversal 
capability (Walters, Deneka-Hannemann et al. 2016). The enhanced mTOR signaling has 
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also been detected in aged tissues (Nacarelli, Azar et al. 2015), while caloric restriction, 
which has been known to decelerate aging, also deactivated mTOR pathway 
(Blagosklonny 2010). Additionally, c-Jun N-terminal kinase (JNK), has been reported 
with senescence suppression role (Lee, Lee et al. 2010). Therefore, we checked p70 
phosphorylation level on threonine 389 and JNK from senescent WI38 cells with or 
without COX inhibitors. Western blot results showed that both sulindac and aspirin 
inhibited p70 phosphorylation level dose-dependently (Figure 4.26 A), indicating that the 
senescent cell clearance effect of NASIDs might come from inhibition of mTOR/p70 
signaling. Also, both sulindac and aspirin up-regulated JNK protein level (Figure 4.26 B), 
suggesting that NASID might also upregulate JNK in order to perform senescent cell 
clearance activity. 
Phosphorylation of p70 negatively regulates autophagosome formation and 
autophagic proteolysis (Blommaart, Luiken et al. 1995, Hara, Yonezawa et al. 1998). 
Thus, we wondered if the cell death induced by NASIDs came from enhanced autophagy. 
The membrane-bound microtubule-associated protein chain 3 (LC3) is one of the most 
specific biomarkers of autophagy, and in mammals, LC3 is expressed in three isoforms, 
a, b, and c. The b form, LC3b, has broad tissue specificities and is widely used as marker 
in autophagy-related studies (Chen, Jiang et al. 2013). Western blot result shows that 
LC3b protein level was sharply decreased with NASIDs administration, indicating that 
the cell death induced through COX inhibition may be autophagy-independent (Figure 
4.26 A). This is in accordance with Figure 4.6 and 4.7, that COX2 KO or inhibition 
suppressed p53 and p21 signaling, since both p53 (Korotchkina, Leontieva et al. 2010) 
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and p21 (Capparelli, Chiavarina et al. 2012) has been reported with autophagy 
stimulation activity. 
Additionally, as senescent MRC5 human lung fibroblasts, induced by DOX, were 
treated with aspirin or celecoxib, a selective COX2 inhibitor (Goldstein, Silverstein et al. 
2000), cell viability was also significantly decreased (4.27 A). The B-cell lymphoma 2 
(Bcl-2) protein family, including Bcl-xL, plays an important role in regulating intrinsic 
apoptotic signaling pathway (Scherr, Gdynia et al. 2016). Directed Bcl-xL inhibition by 
siRNA or small molecule ABT-737 could eliminate senescent cells (Yosef, Pilpel et al. 
2016). Interestingly, the Bcl-xL protein level was also greatly decreased with either 
aspirin or celecoxib administration (Figure 4.27 B), indicating that NASIDs possibly also 
eliminate senescent cells through Bcl-xL inhibition. 
In summary, DOX administration increased COX2 expression, and COX2 
deletion could suppress this COX2 induction. Both in vitro and in vivo, COX inhibition 
could induce elimination of senescent cells and partially rescue DOX-induced aging 
phenotypes, possibly through the suppression of p70 and Bcl-xL pathway. 
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Figure 4.1 COX2 expression increased in tissues of DOX-treated mice. DOX 
treatment increased COX2 protein level in skin (A), liver (B), inguinal fat (C), and 
thymus (D). Protein lysates were made from sonicated tissues (skin, liver, inguinal fat, 
or thymus) from mice treated with either PBS or DOX, in RIPA buffer containing 
HaltTM Protease Inhibitor Cocktail. COX2, actin, and GAP-DH proteins were probed 
with anti-COX2, anti-actin, and anti-GAP-DH primary antibody, respectively. 
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Figure 4.2 Western blot analysis for COX2 in wild-type and COX2 knockout MEFs. 
Protein lysates were made in RIPA Buffer containing HaltTM Protease Inhibitor 
Cocktail. COX2 protein was probed with anti-COX2 antibody. 
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Figure 4.3 COX2 deletion reduced DOX-induced senescence. MEFs were treated with 
either DMSO (control) or 1mM DOX for 2h, and SA-β-gal staining assay was 
performed to detect cellular senescence. (A) Representative photographs of SA-β-gal 
assay after DOX treatment of MEF WT and MEF CO2 KO cells. (B) COX2 deletion 
reduced SA-β-gal-positive cell percentage. 
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Figure 4.4 Transgenic expression of COX2 increases p53 level in vivo. Western blot 
analysis of COX2 and p53 in pancreas, skin, and muscle tissues of control and COX2 
transgenic littermates. 
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Figure 4.5 p53 and p21 expression in tissues of DX-treated mice. DX treatment 
increased COX2 protein level in skin (A), liver (B), inguinal fat (C), thymus (D), 
testicle (E), and lung (F). Protein lysates were made from sonicated tissues (skin, 
liver, inguinal fat, or thymus) from mice treated with either DX or PBS, in RIPA 
buffer containing HaltTM Protease Inhibitor Cocktail. COX2, actin, and GAP-DH 
proteins were probed with anti-COX2, anti-actin, and anti-GAP-DH primary antibody, 
respectively. 
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Figure 4.6 COX2 suppression decreased p53 level upon DOX treatment. WI38 cells 
were treated with PBS/1mM DOX for 2h, with or without COX inhibitors, and protein 
lysates were made in RIPA buffer containing HaltTM Protease Inhibitor Cocktail. 
COX2, p53 and GAP-DH protein were probed with the antibody of each. The final 
concentration of each inhibitor: DuP-697 5µM, aspirin 1µM, celecoxib 2.5µM, and 
piroxicam 20µM. 
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Figure 4.7 COX2 deletion decreased p53 level upon DOX treatment. MEF WT and 
COX2 KO MEFs were treated with 1mM DOX for 2h, and protein lysates were made. 
COX2, p53, p21, and GAP-DH protein were probed with the antibody of each. 
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Figure 4.8 Pharmacological treatment procedure of C57BL/6 with DOX and aspirin. 
2.5mg/kg DOX was intraperitoneally injected four times into C57BL/6 mice when the 
mouse was 2, 3, 4, and 5-week-old. Then mice were fed with 0.02g/100mL aspirin 
water after they were 9-week-old. Various tissues were harvested when the mouse was 
16~18-week-old. 
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Figure 4.9 Aspirin partially recovered DOX-caused body weight loss and white blood 
cell (WBC) loss. body weight gain (A) and WBC cell counts (B) were determined. 
(n=4) 
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Figure 4.10 Aspirin partially recovered DOX-induced inguinal fat loss. (A) A 
representative photograph of inguinal fats (Arrows) after PBS (Control), DOX and/or 
aspirin treatment. (B) A representative photograph of isolated inguinal fats after PBS 
(Control), DOX and/or aspirin treatment. (C) Aspirin treatment partially rescued 
DOX-decreased inguinal fat weight/body weight ratio (n=4). 
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Figure 4.11 Aspirin partially recovered DOX-induced epididymal fat loss. (A) A 
representative photograph of epididymal fats (Arrows) after PBS (Control), DOX 
and/or aspirin treatment. (B) A representative photograph of isolated epididymal fats 
after PBS (Control), DOX and/or aspirin treatment. (C) Aspirin treatment partially 
rescued DOX-decreased epididymal fat weight/body weight ratio (n=4). 
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Figure 4.12 Aspirin partially rescued DOX-induced sperm population decrease. 
Representative photographs of testicle H&E-stained sections after PBS (Control), 
DOX and/or aspirin treatment. 
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Figure 4.13 Aspirin partially recovered DOX-induced tissue weight loss. Tissue 
weight/body weight ratio was partially rescued by aspirin in brown adipose tissue (A), 
testicle (B), and lung (C). n=4. 
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Figure 4.14 Aspirin partially recovered DOX-induced subcutaneous fat loss. Scale bar 
= 100µm. (A) Representative photographs of skin H&E-stained sections after PBS 
(Control), DOX, and/or aspirin treatment. (B) Subcutaneous fat decreased after PBS 
(Control), DOX, and/or aspirin treatment (n=6). The skin sample was embedded into 
paraffin block and sectioned into 5µm sections. Sections were stained with 
hematoxylin and eosin after 1h baking at 60°C within hybridization oven. 
Subcutaneous fat width was measured with ImageJ. 
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Figure 4.15 Aspirin partially recovered DOX-induced muscle fiber size decrease. (A) 
H&E stained sections of hind leg skeletal muscle from PBS (Control), DOX, and/or 
aspirin-treated male littermate. (B) Frequency distribution of skeletal muscle fiber 
cross-sectional area (CSA) between PBS (Control), DOX, and/or aspirin-treated male 
mice. Scale bar = 100µm. 
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Figure 4.16 Aspirin partially recovered DOX-induced fat loss. Representative 
photographs of H&E stained sections of inguinal fat after PBS (Control), DOX, and/or 
aspirin treatment. 
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Figure 4.17 Aspirin partially recovered DOX-induced necrosis in mouse brain. (A) 
Representative photographs of H&E stained sections of brain after PBS (Control), 
DOX, and/or aspirin treatment. (B) Necrotic neuron counting in 250µm2. While DOX 
increased necrotic neuron number, aspirin treatment restored neuron necrosis level. 
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Figure 4.18 DOX-induced cellular senescence was partially rescued by aspirin. 
Aspirin recovered DOX-induced cellular senescence in liver (A), spleen (B), pancreas 
(C), and lung (D) in vivo. Mice were sacrificed, and tissues were immediately 
harvested and embedded in O.C.T. Compound. Cryosections were made from 
embedded samples, and SA-β-gal in vivo assay was performed. 
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Figure 4.19 Aspirin recovered DOX-induced the mRNA level of cellular senescence 
markers, p16 and IL6. p16 and IL6 mRNA levels were determined by real-time 
quantitative PCR. The DOX-induced p16 level was restored by aspirin treatment in 
liver (A), inguinal fat (B), and spleen (C). The DOX-induced IL6 level was restored 
by aspirin treatment in spleen (D), and liver (E). 
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Figure 4.20 Treatment schedule for COX2 knockout induction and SC-236. 
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Figure 4.21 COX2 deletion or selective pharmacological inhibition recovered DOX-
induced body weight loss. (A) COX2 knock-out recovered body weight loss under 
DOX treatment. (B) SC-236, a COX2 specific inhibitor, recovered body weight loss 
under DOX treatment. n=3. 
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Figure 4.22 COX2 deletion or selective pharmacological inhibition recovered 
monocyte population level under DOX treatment. (A) COX2 knock-out recovered 
monocyte population decrease under DOX treatment. (B) SC-236, a COX2 specific 
inhibitor, also recovered monocyte population decrease under DOX treatment. n=3. 
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Figure 4.23 NSAIDs reduced viability of senescent WI38 cells. (A) Senescent WI38 
cell viability was reduced after 100µM and 200µM sulindac treatment; (B) Senescent 
WI38 cell viability was reduced after 1mM, 2.5Mm and 5mM aspirin treatment. Cell 
viability was analyzed by MTT assay. 
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Figure 4.24 NSAIDs decreased cellular senescence level. (A) Representative 
photographs of senescent level decrease, and cell morphology change, after sulindac 
(100µM and 200µM) and aspirin (1mM, 2.5mM and 5mM) treatment. (B) 
Representative cell culture well photographs of SA-β-gal-positive cell number 
generally decreased after sulindac (100µM and 200µM) and aspirin (1mM, 2.5mM 
and 5mM) treatment. 
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Figure 4.25 NSAIDs decreased percentage of senescent cells. SA-β-gal-positive 
population decreased after sulindac (100µM and 200µM) and aspirin (1mM, 2.5mM 
and 5mM) treatment. 
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Figure 4.26 NSAIDs decreased p70, JNK, and LC3b signaling level in senescent 
WI38 cells. (A) p-p70 and LC3B protein level decreased after sulindac (100µM and 
200µM) and aspirin (1mM, 2.5mM and 5mM) treatment, while total p70 protein level 
was generally unchanged. (B) Total JNK protein level increased after sulindac 
(100µM and 200µM) and aspirin (1mM, 2.5mM and 5mM) treatment. 
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Figure 4.27 Bcl-xL signaling was decreased after treatment of COX inhibitors. (A) 
DOX-induced senescent MRC5 cells were treated with aspirin (1 mM) or celecoxib 
(20µM) for 12 days. Treated cells were stained with Calcein AM and DAPI for 
visualization of live and dead cells, respectively. Data are presented as the percent of 
live cells. (B) Western blot analysis of Bcl-xL in senescent MRC5 cells treated with 
1mM aspirin and 20 µM celecoxib for 72 hours. 
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CHAPTER 5 
DISCUSSION 
Increasing evidence has implicated the role of COX2 in aging. Neonatal death and 
renal pathology in global COX2 knockout mice prevents them from being used to study 
the role of COX2 in the aging process (Loftin, Trivedi et al. 2001). We have developed a 
COX2 transgenic mouse model which allows conditional, tissue-specific COX2 
expression (Shim, Foley et al. 2010). Using this model, we have generated tamoxifen-
inducible COX2 transgenic mice to investigate the biological significance of COX2 up-
regulation during aging. When COX2 expression was induced in 5~6-week-old mice, 
COX2 transgenic mice developed various signs of aging such as reduced subcutaneous 
fat, delayed hair growth, chronic pancreatitis, infertility, and decreased muscle fiber size. 
In addition, the lifespan of COX2 transgenic mice was significantly reduced compared to 
that of wild type littermates. All COX2 transgenic mice exhibited at least some of these 
phenotypes characteristic of premature aging, implicating COX2 as a potential target in 
the control of age-related diseases. 
Aging phenotypes observed in other models, such as liver pathologies and 
kyphosis were not observed in our COX2 transgenic model. This may be related to a low 
level of COX2 transgene expression in these tissues. If this is the case, then it suggests 
that the effect of COX2 may be mediated by local production of prostanoids. 
Alternatively, COX2 may differentially affect the physiology of these tissues. For 
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example, prostaglandin E2 (PGE2), a major prostanoid produced by COX2, is a strong 
inducer of bone formation in a variety of animals (Norrdin, Jee et al. 1990), including 
humans. In addition, COX2 has been shown to regulate mesenchymal cell differentiation 
into osteoblast lineage (Zhang, Schwarz et al. 2002). We have also recently shown that 
prostaglandin F2α (PGF2α) stimulates chondrocyte differentiation and promotes bone 
morphogenetic protein (BMP) signaling (Kim and Shim 2015). Thus, increased 
expression of COX2 may protect the skeleton from age-associated damage such as 
osteoporosis, which is frequently observed in other mouse models of aging. COX2 has 
been implicated in inflammatory and degenerative brain diseases (Minghetti 2004). In the 
current study, brain aging in COX2 transgenic animals was not analyzed. However, it has 
been shown that neuronal-specific COX2 transgenic mice develop age-dependent 
cognitive deficits and neuronal apoptosis (Andreasson, Savonenko et al. 2001), 
suggesting that COX2 also contributes to neuronal aging. Moreover, Mirjany et al. 
(Mirjany, Ho et al. 2002) have shown that COX2 accelerates glutamate-induced apoptotic 
damage in neuronal-specific COX2 transgenic mice. 
It is well-known that COX2 plays an important role in inflammation. Chronic 
inflammation is a hallmark of cellular senescence and aging,  and promotes many age-
related diseases (Franceschi, Capri et al. 2007). It has been shown that knockout of the 
nfkb1 subunit of the transcription factor NFκB causes chronic inflammation and 
accelerated aging (Jurk, Wilson et al. 2014). In the same study, ibuprofen, a general COX 
inhibitor, reduced inflammation and restored regenerative capacity of hepatocytes in 
nfkb1-/- mice. However, although COX2 expression caused pancreatitis in our COX2 
transgenic model, the signs of chronic inflammation such as increased tissue infiltration 
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of immune cells and elevated levels of inflammatory cytokines were not observed. This 
suggests that chronic inflammation may not be the mechanism by which COX2 regulates 
the aging process. Currently, how COX2 induces aging phenotypes is not clear. At the 
cellular level, COX2 inhibitors suppressed the replicative senescence, while PGE2 
promoted cellular senescence (Han, Roh et al. 2004, Martien, Pluquet et al. 2013, Chou, 
Ramirez et al. 2014), suggesting the involvement of prostaglandins and their receptors in 
cellular senescence. However, another study has shown that celecoxib, a COX2 specific 
inhibitor, extends the life span of C. elegans and delays the age-associated physiological 
changes via inhibition of insulin-like signaling, but not via COX2 activity (Ching, Chiang 
et al. 2011). On the other hand, a mouse study has shown that generation of reactive 
oxygen species (ROS) increases with age, which may result from increased COX2 
expression and activity in aged animals (Kim, Kim et al. 2000). In our study, signaling 
pathways involving p53 might play a role in COX2-induced senescence and aging, but 
the exact mechanism still needs further study. 
Late effects, which resembles early aging phenotypes, are a profound concern of 
childhood cancer survivors (Larsen, Muller et al. 2003, Armstrong, Kawashima et al. 
2014). Around 200,000 children of the world develop cancer each year, and it was 
estimated that the total number childhood cancer survivors was around 220,000 in the 
United States in the year of 2000 (Bleyer 1990). With age, the risks of late effects in 
childhood cancer survivors are increasing, requiring the imminent need of effective 
therapy to alleviate these early aging phenotypes. In our study, we developed a mouse 
model of chemotherapy-induced aging of childhood cancer survivors, with common 
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chemotherapeutic agent DOX. Our mouse model developed aging phenotypes like 
reduced reproductive ability, decreased fat amount and muscle atrophy. 
Chemotherapy-related mouse models have been developed by many groups, like 
mouse model developed with paclitaxel, a chemotherapeutic agent known to have 
neurotoxic properties, to study chemotherapy-related fatigue (Ray, Trammell et al. 2011), 
mouse model developed with DOX for the same purpose (Zombeck, Fey et al. 2013), 
mouse model of gastric cancer with intravoxel incoherent motion diffusion-weighted 
magnetic resonance imaging to study chemotherapy response evaluation (Cheng, Wang 
et al. 2017), among others. However, all these models were developed from adult mouse, 
making them inappropriate to study the long-term late effects of chemotherapy in 
childhood cancer survivors. Therefore, our mouse model, developed from juvenile mice 
fulfills this imminent need. 
COX2 pathway has been known to maintain senescence and inflammation of 
fibroblasts (Zdanov, Bernard et al. 2007, Dagouassat, Gagliolo et al. 2013). But COX2 
inhibitors, although have been observed with a role in senescence and aging, were 
proposed that this was due to its catalytic activity-independent manner (Kim, Park et al. 
2008, Lee, Kim et al. 2012). In present study, we confirmed that COX2 played an 
essential role in maintaining cellular senescence. COX2 inhibitors, either non-selective 
like aspirin and sulindac, or selective like SC-236 and celecoxib, induced elimination of 
senescent cells both in vitro and in vivo, and in this way alleviated early aging 
phenotypes induced by chemotherapeutic agent like DOX. 
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The mTOR is a serine/threonine kinase responsible for nutrients integration to 
execute cell growth and division (Kim and Guan 2015, Barilari, Bonfils et al. 2017). This 
kinase exists in two complexes of mTORC1 contain RAPTOR and mTORC2 containing 
RICTOR (Kim and Guan 2015, Ito, Yurube et al. 2017). Downstream effectors of 
mTORC1 including p70 regulate cell proliferation, mRNA translation, and protein 
synthesis (Ito, Yurube et al. 2017). Recently, mTOR signaling has been shown to 
promote cellular senescence and aging in various model organisms, and in mice, 
inhibiting mTOR by rapamycin treatment can significantly extend lifespan and many 
age-related diseases (Xu, Cai et al. 2014, Weichhart 2018). Besides, persistent mTOR 
signaling supports senescent cell survival, suggesting manipulating it signaling pathway 
could be a promising way to induce cell death of senescent cells (Carroll, Nelson et al. 
2017). The p70 kinase activity is regulated by many phosphorylation events on amino 
acids within the catalytic and linker domains. Among these, Thr229 phosphorylation in 
the catalytic domain and Thr389 phosphorylation in the linker domains are most 
important for kinase function (Pullen and Thomas 1997), while phosphorylation of 
Thr389 is most closely related with this enzyme’s in vivo activity (Weng, Kozlowski et 
al. 1998). Environmental stresses like ultraviolet (UV) has been reported to induce 
phosphorylation of p70 at Thr389 site (Huang, Li et al. 2002).  Earlier phosphorylation of 
Thr389 is also required for the action of phosphoinositide 3-dependent protein kinase 1 
on Thr229 (Alessi, Kozlowski et al. 1998, Pullen, Dennis et al. 1998). In present study, 
we showed decreased p70 phosphorylation level at Thr389 in senescent cells after 
NSAID treatment, indicating decreased p70 kinase activity, and NSAIDs eliminate 
senescent cells possibly through suppressing this signaling pathway. 
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Autophagy is the major cellular digestion process that removes damaged 
macromolecules and organelles (Kim and Guan 2015), through which a portion of the 
cytoplasm is delivered to lysosomes to be degraded (Kuma, Matsui et al. 2007). mTOR, 
as a central regulator of cell growth, plays a key role at the interface of pathways that 
coordinately regulate the balance between cell growth and autophagy in response 
nutritional status, growth factors and stress signals (Jung, Ro et al. 2010). Autophagy 
induction by genetic or pharmacologic inhibition of mTOR has been reported in many 
organisms like yeast, Drosophila, and mammalian cells (Kim and Guan 2015). Therefore, 
we wondered if the induced senescent cell death by NASIDs was due to increased 
autophagy level. Microtuble-associated protein light chain 3s (LC3s) are structural 
proteins of autophagosomal membranes, and the human LC3 family has three mambers 
LC3a, LC3b, and LC3c (Koukourakis, Kalamida et al. 2015). While LC3b has been 
proposed as ideal marker for monitoring autophagy level (Schlafli, Berezowska et al. 
2015), its protein level after NSAID treatments was surprisingly decreased. While it is 
unclear so far about the mechanism of this phenomenon, LC3b’s decrease with NSAID 
treatments suggests it is unlikely that NSAIDs promote cell death of senescent cells 
through autophagy induction. 
p53 is known to play a pivotal role in cellular homeostasis; thus, dysregulation of 
p53 signaling is linked to aging or to the development of diseases such as cancer. 
Expression of p53 is induced by various cellular or environmental stimuli. Intriguingly, 
many signals that activate p53 are known to induce COX2 expression as well (de Moraes, 
Dar et al. 2007), suggesting the existence of cross-talk between these two pathways. It is 
well-known that p53, as a transcription factor, positively or negatively regulates COX2 
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expression. However, the role of COX2 as an upstream regulator of p53 has not been 
well-studied. We previously have demonstrated that COX2 positively regulates p53 
levels (Ventura, Kirsch et al. 2007). In COX2 transgenic embryos which develop severe 
axial skeletal malformations, accumulation of p53 protein was dramatically increased in 
the precursor cells of the axial skeleton, indicating that COX2 functions as an upstream 
regulator of p53 signaling. Moreover, we recently have shown that doxorubicin-induced 
p53 expression is reduced by inhibition or knockdown of COX2, further supporting the 
role of COX2 in regulating p53 (Kim and Shim 2016). Although the underlying 
mechanism by which COX2 causes elevated levels of p53 warrants further study, 
previous reports suggested that COX2 can regulate p53 through prostaglandin -dependent 
and -independent mechanisms. For example, it has been shown that PGE2 stimulates p53 
activity in human synovial fibroblasts through p38 kinase-mediated phosphorylation of 
p53 (Faour, He et al. 2006). Additionally, PGE2 has been shown to be involved in p53 
activation and maintenance of the senescent phenotype in chronic obstructive pulmonary 
disease (COPD) fibroblasts (Dagouassat, Gagliolo et al. 2013). On the other hand, COX2 
has been shown to induce genomic instability (Singh, Cook et al. 2008) and generate 
reactive oxygen species (Xu, Choudhary et al. 2006) in a prostaglandin-independent 
manner. In the current study, p53 expression was up-regulated in the tissues of COX2 
transgenic mice, suggesting that COX2-mediated p53 activation may contribute to 
premature aging phenotype. Future study with p53 null mice will determine whether 
aging-phenotypes in COX2 transgenic mice are p53-dependent. Likewise, both COX2 
and p53 expression was also up-regulated in tissues of DOX-treated mice, indicating that 
COX2 plays a role in chemotherapy-induced early aging phenotypes, possibly through 
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p53 induction. Additionally, activation of p53 inhibits mTOR activity, and regulates its 
downstream targets like p70 Thr389 phosphorylation level and autophagy (Feng, Zhang 
et al. 2005). However the decreased p50 and p70 Thr389 phosphorylation after NSAIDs 
treatment suggest that the decreased p70 phosphorylation level in our study is not likely 
regulated by p53, which was up-regulated after DOX administration. 
It has long been known that accumulation senescent cells promote aging and age-
related diseases. In 2011, a study using transgenic mice reported that clearance of p18-
positive senescent cells could prevent or delay age-related tissue dysfunction and extend 
healthspan (Baker, Wijshake et al. 2011). Since then, various methods have been 
developed to induce cell death of senescent cells, in order to eliminate them from 
nontransgnic organisms to improve healthspan. Among them, inhibiting Bcl-xL activity 
with siRNAs or small molecule ABT-737 has been shown as an effective way. The Bcl2 
protein family, including Bcl-xL, is mainly known for its pivotal role in the regulation of 
the mitochondrial death pathway (Scherr, Gdynia et al. 2016). Under physiological 
conditions, pro-apoptotic members like Bax and Bak are sequestered and thereby 
inhibited by anti-apoptotic relative like Bcl-xL. If apoptotic stimuli like DNA damage 
occur, pro-apoptotic proteins get released from their binding, leading to subsequent 
mitochondrial activation and initiation of the downstream apoptosis cascade (Cory and 
Adams 2002, Scherr, Gdynia et al. 2016). Here we show that NSAIDs could reduce Bcl-
xL protein level. This indicates that NSAIDs may initiate cell death of senescent cells by 
releasing pro-apoptotic proteins through both p70 and Bcl-xL signaling inhibiton. In 
support to this, co-targeting Bcl2 and mTOR-p70 pathway has also been reported 
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recently as an effective way to trigger synergistic apoptosis (Iacovelli, Ricciardi et al. 
2015). 
Each available senolytic drugs so far has critical disadvantage to prevent it from 
immediate usage: Quercetin, ABT263/737 and FOXO4-DRI are not FDA-approved, and 
while quercetin, dasatinib, ABT263/737 are non-specific (Zhu, Tchkonia et al. 2016, 
Baar, Brandt et al. 2017). NSAIDs used in this study have been FDA-approved and 
showed specificity toward senescent cells. With this we propose NSAIDs like aspirin, 
have strongly promising potential to be developed as a new generation of senolytic drugs 
to induce senescent cell elimation. 
COX2 expression is increased in many age-related human diseases and in the 
tissues of aged humans and mice, implicating the involvement of COX2 in the aging 
process. However, the biological significance of increased COX2 expression during 
aging has not been determined. Our data suggest that targeting of COX2 and its 
downstream pathways may have therapeutic and preventive potential against aging and 
age-related diseases. In summary, we first found that COX2 overexpression in mice 
caused increased cellular senescence and aging phenotypes. DOX treatment was also 
discovered with induction effect on cellular senescence and aging. Importantly, DOX 
administration also caused increased COX2 expression, and COX2 deletion antagonized 
cellular senescence level, indicating DOX induces aging through elevated cellular 
senescence, which is mediated by COX activity. Therefore, we tried to manipulate COX 
level to rescued cellular senescence and aging. As result, COX inhibitors successfully 
decreased senescence level, and aging phenotypes caused by DOX administration, 
possibly through suppression of p70 and Bcl-xL signaling. Our study indicates that COX 
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inhibitors, or NASIDs, can be developed as new generation of senolytic drugs to reduce 
late effects of chemotherapy and improve healthspan. 
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CHAPTER 6 
MATERIALS AND METHODS 
6.1 GENERATION OF COX2 TRANSGENIC MICE 
All animal studies and procedures were approved by the University of South 
Carolina Institutional Animal Care and Use Committee. The transgenic basic cassette, 
pCAG-CAT-HES-poly(A), was a gift from Dr. Junichi Miyazaki (Osaka University 
Medical School, Japan). Human COX2 cDNA was inserted into HindIII and EcoRV sites 
of pCAG-CAT-HES-poly(A). The transgenic vector was digested with SalI and PstI to 
remove the vector region. The insert fragment was recovered from the gel and diluted to 
2μg/ml concentration in 1 mM Tris/HCl (pH 8.0) and 0.1mM EDTA. The DNA fragment 
was introduced into pronuclei of 0.5-day-old mouse embryos (B6D2F1, Taconic) by 
glass capillaries. Injected embryos were cultured in KSOM (Sigma) for 1 day, and 
embryos that reached the two-cell stage were transferred into oviducts of pseudopregnant 
females. The offspring was initially screened by PCR for the chloramphenicol 
acetyltransferase (CAT) gene from tail tissue (CAT2 primer, 5’-
CAGTCAGTTGCTCAATGTACC-3’; CAT3 primer, 5’-ACTGGTGAAACTCACCCA-
3’). For production of the CATflCOX2 mice, five lines were initially established, and two 
of them, lines 12 and 17, showing high CAT activity in the liver, were chosen for further 
analysis. ROSA-Cre ERT2 mice were obtained from the Jackson Laboratory. A ROSA-
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Cre ERT2 female (or CATflCOX2 female) mouse was housed overnight with a 
CATflCOX2 male (or ROSACre ERT2 male) mouse. 
6.2 GENOTYPING AND PHARMACOLOGICAL TREATMENT OF MICE 
Genomic DNA was isolated from tails using a DNeasy kit (Qiagen). Isolated 
genomic DNA was amplified using ExTaq DNA polymerase (Takara) with a primer set 
designed to detect the presence of a recombined human COX2 allele (forward primer, 5’-
GTGCTGGTTATTGTGCTGTCTC-3’; reverse primer, 5’-
TCTCCATAGAATCCTGTCCGGGTA-3’), and PCR products were run on 1.2% 
agarose gel. The recombined human COX2 allele was identified as a 300 bp PCR 
product, whereas the non-recombined human COX2 allele was identified as a 1.8 kb 
fragment. To detect the presence of the Cre gene, genomic DNA was amplified by PCR 
using a primer set for Cre (forward primer, 5’-ACCTGAAGATGTTCGCGATTATCT-
3’; reverse primer, 5’-ACCGTCAGTACGTGAGATATCTT-3’). 
In order to induce COX2 expression, 100μl of tamoxifen (10mg/ml in corn oil) 
was intraperitoneally injected every 3 days, for a total of three times, to 5-week-old 
control (wild type, CATflCOX2, or Rosa-CreERT2) and transgenic (CATflCOX2:Rosa-
CreERT2) mice. Aspirin treatment was administrated to mice by dissolving aspirin 
(Sigma-Aldrich, St. Louis, MO) (0.025mg/mL) in feeding sterile water. SC-236 was first 
dissolved in DMSO, and then in water. Mice were intraperitoneally injected with SC-236 
at concentration 2mg/kg, every 3 days for 2 weeks (total injection 5). 
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6.3 HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
Mouse tissues were collected, fixed in 10% neutral buffered formalin, and 
embedded in paraffin blocks. Tissue sections (5μm) were subjected to hematoxylin-eosin 
(H&E) staining by standard procedures. For immunohistochemical analysis, antigen 
retrieval was performed by immersing sections in 10mM sodium citrate (pH 6.0) at 95°C 
for 30 min. Sections were incubated with primary antibody [human COX2 (1:500), 
Cayman Chemical; p16 (1:500), Santa Cruz Biotechnology; cleaved caspase-3 (1:250), 
Cell Signaling] at 4°C overnight. For detection of p-H2AX, sections were subjected to 
EDTA (1mM, pH 8.0) antigen retrieval for 20 min and incubated with primary antibody 
[p-H2AX (Ser139) (1:500), Cell Signaling] at 4 °C overnight. Washed sections were 
incubated in the ImmPress reagent (Vector Laboratories) for 30 min and visualized with 
diaminobenzidine. After mounting, the sections were observed under an Oympus BX51 
light microscope, and the image was acquired by an AxioCam MRc camera. For 
cryosections, freshly harvested tissues were imbedded into Tissue-Tek O.C.T. Compound 
(Sakura Finetek USA Inc. Torrance, CA), and sections were made at 5μm. 
6.4 ISOLATION OF MOUSE LUNG FIBROBLASTS AND SA-Β-GALACTOSE IN 
VITRO STAINING 
Isolation of adult mouse lung fibroblasts from control and transgenic mice was 
carried out as described (Seluanov, Vaidya et al. 2010). For SA-β-galactose staining, 5 x 
105 fibroblasts were plated in 60 mm culture dishes, and incubated with 1µM 4-
hydroxytamoxifen (Sigma) for 24 hours. Forty eight hours after 4-hydroxytamoxifen 
treatment, the cells were fixed in 2% formaldehyde/0.2% glutaraldehyde, washed with 
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phosphate-buffered saline, and incubated at 37°C overnight in stain solution [1mg/ml 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal), 40mM citric acid-sodium 
phosphate (pH 6.0), 150mM NaCl, 2mM MgCl2, 5mM potassium ferrocyanide, 5mM 
potassium ferricyanide]. 
6.5 CELL CULTURE 
WI38 and MRC5 cells were obtained from the American Type Culture Collection 
(ATCC), and were grown in regular cell culture medium (DMEM supplemented with 
10% BS and gentamycin). 0.25x106 cells were plated in 35mm cell culture dish. 24 hours 
later, cells were treated with 1mM doxorubicin for 2 hours, washed with sterile 
phosphate-buffered saline (PBS), and replaced with fresh cell culture medium. 72 hours 
later, cells were treated with various concentrations of NASIDs. 
6.6 WESTERN BLOT ANALYSIS 
Cells were washed with cold PBS, and lysed on ice in modified RIPA buffer 
(50mM Tris-HCl, pH 7.4, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 1mM Na3VO4, 
10mM NaPPi, 10mM glycerophosphate and 50mM NaF) supplemented with the Halt 
protease inhibitor cocktail (Thermo Scientific). Tissues were also lysed in RIPA buffer, 
and protein concentration was measured using a BCA protein assay kit (Pierce). Equal 
amounts of protein were heated at 65 °C in LDS sample buffer (Invitrogen) with sample 
reducing agent (Invitrogen) for 10 min and then separated by SDS-PAGE. The separated 
proteins were transferred to an Immobilon-P membrane (Millipore). Following 
incubation in blocking buffer (TBS with 5% nonfat dry milk and 0.1% Tween 20) for 1 
hour at room temperature, the membranes were incubated with primary antibodies [p53 
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(1:2000), Cell Signaling; GAP-DH (1:5000), Cell Signaling; human COX2 (1:500), 
Cayman Chemical] diluted in blocking buffer overnight at 4°C. The membranes were 
washed and then probed with a horseradish peroxidase-linked secondary antibody (Cell 
Signaling) for 1 hour at room temperature. Detection was made with an enhanced 
chemiluminescence reagent (GE Healthcare Life Sciences), followed by exposure of 
membrane to film. 
6.7 REAL-TIME PCR 
RNA was isolated using an RNeasy kit (Qiagen) and treated with 1 unit of 
amplification grade DNase I (Invitrogen) per 1µg RNA at room temperature for 15min to 
remove genomic DNA followed by inactivation of the DNase I with 2.5mM EDTA (pH 
8.0) and incubation at 65°C for 5min. Reverse transcription was done with 2µg total RNA 
using SuperScript II reverse transcription system (Invitrogen) according to the 
manufacturer’s instructions. Quantitative real-time PCR analysis was conducted using a 
GoTaq® qRCR mixture (Promega). Reactions were run in triplicate for three independent 
experiments. The mean of housekeeping gene GAP-DH was used as an internal control to 
normalize the variability in expression levels. Expression data were normalized to the 
mean of GAP-DH to control the variability in expression levels and were analyzed using 
the 2-ΔΔCT method. 
6.8 MTT ASSAY 
0.09x106 cells were plated to each well of 96-well plate, together with 100µL cell 
culture medium. 24 hours later, cells were treated with 1mM doxorubicin for 2 hours, 
washed with sterile phosphate-buffered saline (PBS), and replaced with fresh cell culture 
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medium. 72 hours later, cells were treated with various concentrations of NASIDs. To 
measure cell viability, 20µL 5mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma-Aldrich, St. Louis, MO), dissolved in PBS, 
was added to each well. Plate was incubated for 2.5 hours in 37°C. Then culture medium 
was replaced with 150µL DMSO in each well, and plate was kept in the dark on The 
Belly Dancer (Stovall Life Science Inc., Greensboro, NC) for 20min. Each well of the 
plate was read under absorbance of 490nm by Synergy HT microplate reader (BioTek 
Instruments, Inc., Winooski VT). 
6.9 SA-B-GAL IN VIVO ASSAY 
Cryosections were first rinsed with PBS, and then fixed with G/F fixative solution 
[0.2% glutaraldehyde (Sigma-Aldrich, St. Louis, MO), 1.85% formaldehyde (Sigma-
Aldrich, St. Louis, MO) in PBS] for 3min, before rinsed with PBS twice. Sections were 
stained in staining solution [1mg 5-bromo-4-chloro-3-indolyl β-D-galactoside (X-gal, 
Sigma-Aldrich, St. Louis, MO), 40mM citric acid/sodium phosphate pH 6.0 (Sigma-
Aldrich, St. Louis, MO), 5mM potassium ferrocyande (Sigma-Aldrich, St. Louis, MO), 
5mM potassium ferricyanide (Sigma-Aldrich, St. Louis, MO), 150mM NaCl (Sigma-
Aldrich, St. Louis, MO), 2mM MgCl2 (Sigma-Aldrich, St. Louis, MO)] for overnight at 
37°C, before rinsed with PBS. Sections were then stained with eosin Y (Sigma-Aldrich, 
St. Louis, MO). 
6.10 STATISTICS 
Statistical analysis was performed using Prism software (Graphpad Software, La 
Jolla, CA). Values of p≤0.05 were considered statistically significant. Statistical 
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significance is indicated by asterisks in figures: * for p values <0.05, ** for p values 
<0.01, *** for p values <0.001, and **** for p values <0.0001. 
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